Rapid-recall takeaways distilled from the MRCPsych Paper B question bank, grouped by specialty. One pearl per high-frequency concept. Use it for last-pass revision alongside questions, not as a replacement for them.
720 pearls · 9 specialties · Generated 6 November 2026
Critical Review
80 high-yield facts
For non-inferiority, the entire confidence interval must fall within the margin; if the lower bound crosses the margin, non-inferiority is not established regardless of the point estimate.
Theoretical sampling is analysis-driven participant selection unique to grounded theory - researchers recruit participants who can develop, challenge, or refine emerging theoretical categories until saturation is achieved.
Lincoln and Guba's framework of credibility, transferability, dependability, and confirmability provides the foundational quality criteria for qualitative research - these parallel but are distinct from quantitative concepts of validity, generalisability, reliability, and objectivity.
Ecological fallacy = group-level associations cannot be transferred to individuals - useful for hypothesis generation but never for individual-level causal inference (Kirkwood & Sterne).
Point prevalence is approximately incidence multiplied by duration - cross-sectional surveys in healthcare settings systematically overrepresent conditions with longer duration or length of stay.
When cases cannot reliably self-report and proxy informants are used, differential measurement of exposure between cases and controls threatens validity - objective records should supplement or replace recall-based exposure assessment.
In case-control studies, increasing controls beyond a 4:1 ratio provides minimal additional statistical power - focus resources on maximising case ascertainment rather than recruiting excessive controls.
Parallel group RCTs are the gold standard design when carryover effects, disease progression, or ethical concerns preclude crossover designs.
Attrition bias in cohort studies is most concerning when dropout is systematic (MNAR) - the characteristics of those lost should always be compared with completers to assess potential bias.
Matching in case-control studies controls for confounding but requires conditional logistic regression for valid analysis - matched variables cannot themselves be studied as risk factors.
Child and Adolescent Psychiatry
80 high-yield facts
Methylphenidate and tics - does not reliably worsen tics; don't withhold ADHD treatment for tics; monitor and adjust; NIMH MTA study evidence; 50-60% of Tourette's have ADHD; alternatives if tics worsen: atomoxetine, guanfacine; tics peak at 10-12 and naturally improve; CBIT for tic management; clonidine as tic adjunct.
M-CHAT-R/F - gold standard ASD screening for toddlers (16-30 months); 20 items, parent-completed; follow-up interview reduces false positives; score ≥8 = immediate referral; early signs: no babbling 12m, no words 16m, no pointing, regression; early diagnosis enables early intervention; ADOS-2 for diagnostic assessment; health visitor developmental reviews at 2-2.5 years.
ARFID in ASD - driven by sensory sensitivities and insistence on sameness, not body image; 50-70% of ASD children have feeding difficulties; assess nutritional status; food chaining technique; multidisciplinary approach (dietitian, OT, SALT); never force food; DSM-5 diagnosis; differentiate from anorexia nervosa; gradual systematic desensitisation; supplement deficiencies.
Afternoon symptom return - add IR 'booster' or switch to longer-acting formulation; Concerta XL ~12 hours; Equasym/Medikinet XL ~8 hours; match formulation to child's daily needs; keep total daily dose equivalent; don't double morning dose; combination approach often works; consider homework, activities, family routine when choosing formulation.
Late female ASD diagnosis - camouflaging, internalising presentation, male-biased diagnostic tools, clinician bias, misattribution to other conditions; average 4-5 years later than males; female phenotype: social masking, people-focused interests, internalising; ratio decreasing (4:1 → 3:1, possibly 2:1); ADOS-2 may miss masking; consider ASD in treatment-resistant anxiety/depression/eating disorders in females.
ASD - two core domains: social communication/interaction deficits AND restricted/repetitive behaviours; DSM-5 requires both; three severity levels; ADOS-2 gold standard; symptoms in early development; may not manifest until demands exceed capacity; parallel play, limited eye contact, repetitive behaviours, insistence on sameness = classic presentation.
Organisation and Delivery of Services
80 high-yield facts
CRHT gatekeeping means assessing all potential admissions to determine whether home treatment is safe and appropriate - it is a clinical assessment function, not a barrier to admission, and when effective can divert 20-30% of admissions.
The Triangle of Care framework promotes equal partnership between service users, carers, and professionals - its six standards address carer identification, staff training, information sharing, carer support posts, induction, and support services.
EIP services aim to minimise DUP to less than 3 months - the access standard requires treatment within 2 weeks of referral, and longer DUP is consistently associated with poorer outcomes across multiple domains.
AOT caseloads of 10-12 (versus CMHT 25-35) enable the intensive, flexible engagement that defines the model - fidelity to small caseloads is essential for effectiveness, and increasing them diminishes outcomes.
The critical period (first 3-5 years) after psychosis onset represents maximum vulnerability but also maximum potential for change - intensive EIP intervention during this window can significantly alter the long-term trajectory of the illness.
The EIP access standard requires treatment within 2 weeks of referral for at least 60% of first-episode psychosis patients - this reflects the critical importance of minimising DUP and was introduced as part of the Five Year Forward View for Mental Health.
CPNs are the backbone of community mental health care - they provide care coordination, medication management, mental state monitoring, psychosocial interventions, and recovery support, often serving as patients' primary point of contact with secondary services.
IPS uses 'place then train' - rapid placement in competitive employment with ongoing integrated support, achieving approximately 55% employment rates versus 25% with traditional approaches - it is a NICE-recommended component of EIP care packages.
OTs focus on enabling meaningful occupation across self-care, productivity, and leisure - their unique contribution to CMHTs is assessing and promoting functional ability and participation, aligning naturally with recovery-focused practice.
Substance Misuse and Addictions
80 high-yield facts
FASD - leading preventable cause of intellectual disability; FAS: facial dysmorphology (smooth philtrum, thin upper lip, short palpebral fissures) + growth restriction + CNS abnormalities; affects ~2-5% of births; no safe alcohol level in pregnancy; often undiagnosed/misdiagnosed; brain vulnerable throughout pregnancy; spectrum from mild to severe; lifelong consequences; UK CMO recommends abstinence in pregnancy.
Acamprosate - first-line (NICE CG115); glutamate modulation; 666mg TDS; 12 months; diarrhoea main side effect. Naltrexone - opioid antagonist; 50mg daily; blocks rewarding effects; can't use with opioids; monitor LFTs.
Oxazepam - glucuronidation (Phase II); safe in liver disease; no active metabolites; LOT mnemonic (Lorazepam, Oxazepam, Temazepam); Phase I impaired in liver disease; Phase II relatively preserved; diazepam/chlordiazepoxide accumulate in liver disease (active metabolites); increased benzodiazepine sensitivity in cirrhosis; risk of hepatic encephalopathy; careful monitoring essential.
Alcoholic cerebellar degeneration - vermal atrophy; gait ataxia prominent; lower limbs > upper limbs; direct toxicity + thiamine deficiency; Purkinje cell loss; MRI: superior vermal atrophy; ~30% of chronic drinkers; may partially improve with abstinence; largely irreversible; differentiate from Wernicke's (acute, ophthalmoplegia, confusion); develops over weeks-months.
SASQ - single screening question; 'How often 6+ units on one occasion?'; sensitivity ~80-90%; takes seconds; gateway to full AUDIT; IBA (Identification and Brief Advice); tiered screening approach; positive monthly or more; Public Health England promotes IBA; efficient for busy settings; validated against full AUDIT; AUDIT question 3 also useful.
Units = ml × ABV% ÷ 1000; pint of 5% beer = 2.8 units; standard glass of wine (175ml, 13%) = 2.3 units; bottle of wine = ~10 units; recommended ≤14 units/week; retrospective drinking diary most accurate; patients often underestimate; this patient at ~48 units/week = high-risk (>3x recommended); specific enquiry better than general questions.
MUP Scotland - 50p per unit (May 2018), increased to 65p (2024); reduces consumption, especially among heaviest drinkers; greatest impact on cheap, strong products; Sheffield model predicted effects; supported by Canadian evidence; 10% price increase → ~9% fewer admissions; WHO recommends pricing policies; population-level intervention; minimal impact on moderate drinkers; Public Health Scotland evaluation data supportive.
Forensic Psychiatry
80 high-yield facts
Fitness to plead - Pritchard criteria (1836); 6 abilities: plead, understand charges, understand guilty/not guilty, instruct counsel, challenge jurors, follow proceedings; determined by judge on medical evidence (2 doctors, 1 Section 12 approved); if unfit: trial of the facts (did the act?); disposals: hospital order, supervision, absolute discharge; causes: psychosis, LD, dementia, ABI; Law Commission recommended reform (not yet implemented); different from insanity defence.
Section 7 guardianship - community care framework; 3 powers: reside at specified place, attend for treatment/education, grant access; guardian usually local authority; 16+ years; 6 months (renewable); 2 medical recommendations + AMHP; no forced treatment; no return power (patient can walk away); mainly used for LD/dementia; infrequently used; welfare of patient or protection of others; residence requirement key power; less coercive than CTO.
Nearest relative - statutory hierarchy (Section 26); powers: apply for admission, object to Section 3, request discharge (Section 23), be consulted; objection to Section 3 prevents application; AMHP can displace NR via County Court (Section 29); RC can bar discharge (Section 25 'barring certificate'); cohabitant of 6+ months can be NR; patient can apply to displace NR (post-2007); Law Commission recommended 'nominated person' replacement; elder takes priority within category.
Malingering assessment - inconsistencies (reported vs observed); atypical symptoms; SIRS-2 (most validated tool); TOMM (cognitive); M-FAST (screening); overly dramatic or vague symptoms; lack of collateral evidence; sudden onset with legal proceedings; observation in unguarded moments; genuine patients often minimise symptoms; can coexist with genuine disorder; diagnose positively; repeated assessments; detailed symptom descriptions; nursing staff observation.
Diminished responsibility - Section 2 Homicide Act 1957 (amended 2009); partial defence: murder → voluntary manslaughter; 4 limbs: abnormality of mental functioning + recognised medical condition + substantially impaired (understand/rational judgement/self-control) + explains killing; burden on defence (balance of probabilities); discretionary sentencing; common: depression, psychosis, PD, ASD; not a complete defence; 2009 modernised the test; significant contributory factor (not sole cause).
Old Age Psychiatry
80 high-yield facts
NPH triad - gait apraxia, urinary incontinence, dementia ('wet, wacky, wobbly'); ventriculomegaly disproportionate to atrophy (Evans' index >0.3); potentially reversible with VP shunt; gait responds best; CSF drainage test predicts shunt response; response rate ~60-80%.
DoLS - six assessments: age, mental disorder, lacks capacity, best interests, eligibility, no refusals; Cheshire West acid test: continuous supervision + not free to leave; maximum 12 months; urgent authorisation for 7-14 days; person can challenge at Court of Protection; RPR must be appointed.
DLB + antipsychotics = dangerous - severe neuroleptic sensitivity (~50%); caused by pre-existing dopamine deficit + D2 blockade; potentially fatal; use cholinesterase inhibitors first for hallucinations; if essential, very low-dose quetiapine or clozapine with extreme caution.
ACE-III assesses 5 domains - attention, memory, fluency, language, visuospatial (total 100); better than MMSE at detecting early impairment; different dementia subtypes produce characteristic profiles; VLOM ratio helps distinguish AD from FTD; takes 15-20 minutes; free to use.
Advance care planning - start as early as possible after dementia diagnosis while capacity is preserved; includes ADRT, LPA, and preference statements; NICE NG97 recommends discussing at diagnosis; capacity must be assessed for each decision; covers place of care, treatment preferences, and end-of-life wishes.
AD pathology - Aβ plaques (extracellular) + neurofibrillary tangles (intracellular hyperphosphorylated tau); amyloid cascade hypothesis; Braak staging of tau spread correlates with symptoms; APOE ε4 is the strongest genetic risk factor for late-onset AD; synaptic loss best correlates with cognitive decline.
ChEIs work better in DLB than AD because the cholinergic deficit is MORE severe but post-synaptic receptors are PRESERVED - more to gain from enhancing ACh levels; particularly effective for visual hallucinations; NICE recommends ChEIs for mild-moderate DLB; also consider for PDD.
ChEIs provide ~2-4 MMSE point benefit vs placebo over 6-12 months; symptomatic, not curative; review at 6 months then annually; continue as long as beneficial; stopping can cause rapid decline; assess cognition, function, behaviour, and carer input; involve patient and family in decisions.
General Adult Psychiatry
80 high-yield facts
Lithium levels MUST be measured at 12 hours post-dose (trough level) - incorrect timing is the most common cause of misleading results; different lithium brands are NOT interchangeable due to bioavailability differences; check every 3-6 months once stable.
Fluoxetine 60mg for bulimia - RCTs showed 60mg superior to 20mg (20mg ≈ placebo); only medication licensed for bulimia in the UK; reduces binge-purge frequency ~50%; use as adjunct to psychological treatment, not sole treatment; serotonergic dysfunction underlies bulimia.
Pregabalin binds α2δ subunit of calcium channels - does NOT act on GABA receptors despite being a GABA analogue; rapid onset anxiolytic; Schedule 3 controlled drug since 2019; taper gradually; second-line for GAD per NICE.
All NSAIDs increase lithium levels - for gout in lithium patients, use colchicine or corticosteroids instead; if an NSAID is unavoidable, reduce lithium dose and check levels within a week; low-dose aspirin (75-150mg) has minimal effect.
Paranoid PD - pervasive distrust and suspiciousness without psychotic symptoms; Cluster A (odd/eccentric); distinguish from paranoid schizophrenia (no hallucinations or delusions) and delusional disorder; shares genetic liability with schizophrenia spectrum; therapeutic alliance is the main treatment challenge.
Antipsychotic-induced hyperprolactinaemia causes hypogonadism and bone loss - monitor prolactin, menstrual function, and consider DEXA in prolonged amenorrhoea; switching to aripiprazole or quetiapine can resolve hyperprolactinaemia.
NICE recommends structured psychoeducation and CBT alongside pharmacotherapy for bipolar disorder - psychoeducation reduces relapse rates; key elements include recognising prodromes, sleep hygiene, substance avoidance, and relapse prevention planning.
Clozapine should be offered after failure of two adequate antipsychotic trials - it is the gold standard for treatment-resistant schizophrenia and is the only antipsychotic with evidence for reducing suicidality in schizophrenia.
Learning Disability Psychiatry
80 high-yield facts
STOMP implementation requires systematic review of all psychotropic prescribing in LD - where no clear psychiatric diagnosis exists, gradual dose reduction (25% every 4-8 weeks) with enhanced monitoring and strengthened PBS is the recommended approach.
Oral lorazepam is first-line for acute behavioural crisis - escalate to IM only if oral route fails, always attempt de-escalation first, and conduct post-incident review to strengthen the PBS plan and prevent recurrence.
People with LD die 16-20 years earlier than the general population - cardiometabolic monitoring on antipsychotics is essential, and the LeDeR programme has highlighted preventable deaths requiring proactive health management.
FASD is the commonest preventable cause of LD - the diagnostic facial triad is smooth philtrum, thin upper lip, and short palpebral fissures, with neurobehavioural problems often persisting into adulthood.
PKU is the classic example of a treatable cause of LD - autosomal recessive inheritance, detected by newborn screening, and prevented by lifelong phenylalanine-restricted diet started in the neonatal period.
Prader-Willi syndrome results from loss of paternally-expressed genes at 15q11-13 (deletion in 70%) - it is the paradigm of genomic imprinting, with the same region causing Angelman syndrome when the maternal copy is lost.
The MCA 2005's first principle is the presumption of capacity - this applies equally to people with LD, capacity is always decision-specific and time-specific, and all practicable steps to support decision-making must be taken before concluding incapacity.
Lesch-Nyhan syndrome (X-linked, HGPRT deficiency) is the paradigm of genetic self-injurious behaviour - the compulsive lip and finger biting is ego-dystonic, with affected individuals often requesting restraint despite being unable to stop the behaviour.
Monitor for Alzheimer's disease in all adults with Down syndrome from age 30 using baseline assessments - APP gene triplication on chromosome 21 causes near-universal neuropathology by age 40, and clinical dementia prevalence increases substantially after age 50.
Psychotherapy
80 high-yield facts
Winnicott's 'holding environment' describes the therapist's provision of reliable, consistent, empathic containment - paralleling good-enough maternal care, it enables the patient to safely explore painful material and develop a more authentic sense of self.
Socratic questioning guides patients to examine their own cognitions through collaborative empiricism - the therapist asks rather than tells, using questions to help patients discover alternative perspectives and evaluate evidence for themselves.
Mental filter (selective abstraction) involves selectively attending to negative details while ignoring positive context - it is one of Beck's key cognitive distortions in depression and is challenged by examining the full picture rather than the filtered version.
Resistance is the unconscious opposition to the therapeutic process - rather than an obstacle, it reveals the patient's defensive patterns and provides crucial therapeutic material about what is being avoided and why.
Repression unconsciously excludes threatening material from awareness - in therapy it manifests as sudden topic changes, 'forgetting,' and avoidance of anxiety-provoking material, and is distinguished from conscious suppression.
Intellectualisation engages with threatening material cognitively while avoiding emotional experience - it is a neurotic-level defence that protects against overwhelming affect but prevents emotional processing when used persistently.
The hot cross bun model shows the reciprocal connections between thoughts, emotions, physical sensations, and behaviours - this means therapy can intervene at any point in the cycle, and the most accessible entry point varies by patient.
ERP reduces OCD through habituation and inhibitory learning - exposure to feared stimuli while preventing the compulsive response allows anxiety to naturally decrease and creates new learning that feared consequences do not occur.
Wells' metacognitive model targets beliefs about worry (metacognitions) rather than worry content - positive metacognitive beliefs maintain worry initiation, while negative metacognitive beliefs about worry's dangerousness generate the distress characteristic of GAD.
Case-control studies select on outcome and look back at exposure - they are the design of choice for rare diseases and produce odds ratios as their measure of association.
Relative risk is the ratio of disease incidence in exposed versus unexposed groups, can only be calculated from cohort studies or RCTs, and a value of 1.0 indicates no association.
The healthy worker effect creates falsely low mortality in employed populations - occupational studies should use internal comparisons or compare with similar professional groups rather than the general population.
Unmatched case-control studies with multiple exposures require unconditional logistic regression to produce adjusted odds ratios - conditional logistic regression is reserved for individually matched designs.
or report past exposures. Patients who have experienced psychosis may ruminate more on potential causes and recall stressful events more readily or with greater detail than healthy controls who have no particular reason to search their memory for stressful experiences.
Cluster randomisation is chosen to prevent contamination when interventions operate at a group level, but always requires inflation of sample size to account for intracluster correlation.
Intention-to-treat analysis is the gold standard for RCTs because it preserves the prognostic balance created by randomisation, even when adherence is imperfect.
NNT = 1/ARR; lower NNTs indicate greater treatment benefit, and most effective psychiatric medications have NNTs between 3 and 10.
The odds ratio = (a×d)/(b×c) is the measure of association for case-control studies; it approximates the relative risk when the disease is rare in the population (rare disease assumption).
Allocation concealment prevents selection bias before randomisation; blinding prevents performance and detection bias after randomisation - both must be evaluated separately.
Multiple imputation is the gold standard for MAR data - it generates multiple datasets, preserves uncertainty, and is superior to single imputation methods like LOCF or mean substitution.
The CONSORT flow diagram is essential for assessing selection bias, attrition bias, and the generalisability of RCT findings by making participant flow transparent at every stage.
Never match on the exposure of interest or variables on the causal pathway between exposure and outcome - this constitutes overmatching and will obscure genuine associations.
Repeated cross-sectional surveys track population-level trends by sampling independently at each time point - they complement longitudinal studies by avoiding attrition bias while sacrificing the ability to track individual trajectories.
IPA is identified by its focus on individual meaning-making, small homogeneous samples, detailed idiographic analysis, and the double hermeneutic - it explores how people make sense of significant personal experiences.
Thematic analysis following Braun and Clarke's six phases is theoretically flexible, not tied to any epistemology, and is distinguished from grounded theory by its lack of iterative sampling and theory-building requirements.
Triangulation uses multiple sources, methods, researchers, or theories to develop comprehensive understanding - discrepancies between sources reveal complexity rather than indicating error.
When a significant carryover effect is detected in a crossover trial, only first-period data should be analysed, sacrificing the efficiency advantage of the crossover design.
Prospective cohort studies establish temporality by following participants from exposure to outcome, but cannot eliminate confounding - only randomisation can balance unmeasured confounders.
Cross-sectional studies cannot establish temporality because exposure and outcome are measured at the same time point - the observed association may reflect forward causation, reverse causation, or confounding.
A hazard ratio is the ratio of instantaneous event rates between groups - it is derived from survival analysis, accounts for censoring, and assumes the ratio remains constant over time (proportional hazards assumption).
Imperfect specificity at low prevalence generates many false positives that inflate apparent prevalence - confirm screen positives with a diagnostic interview (two-stage design) for accurate community estimates.
Confounding by indication is a critical concern in observational drug studies - patients prescribed a specific medication differ systematically from those prescribed alternatives, making direct outcome comparisons misleading.
Factorial designs are efficient because they test multiple interventions simultaneously, but significant interactions between factors complicate interpretation and reduce the power advantage.
Grounded theory is identified by its iterative cycle of data collection, coding, and theoretical sampling - data collection continues until theoretical saturation is reached and a substantive theory emerges from the data itself.
Focus groups capture social interaction but are vulnerable to conformity effects and power dynamics - mixing hierarchical levels within groups can suppress honest opinions, particularly on sensitive or contentious topics like ECT.
Person-years at risk is calculated by summing each participant's actual follow-up time, providing an accurate denominator that accounts for deaths, withdrawals, and losses to follow-up.
Clinic-based cross-sectional studies suffer from selection bias because attendees differ systematically from the broader disease population - always consider whether the sample represents the target population when interpreting prevalence estimates.
Ecological confounding involves area-level variables that confound the aggregate association - these cannot be controlled using individual-level statistical methods and are a fundamental limitation of ecological study design.
Controls should represent the source population from which cases arise - hospital-based controls risk Berkson's bias when the reason for attendance is related to the exposure under study.
Nested case-control studies gain efficiency by sampling from within a defined cohort - they preserve temporal sequence, eliminate recall bias for prospectively collected data, and are ideal when exposure measurement is costly.
Reflexivity is the systematic examination of the researcher's influence on the research process - it is a hallmark of quality in qualitative research and is particularly important when researchers hold positions of power relative to participants.
Stratified randomisation is used to ensure balance of key prognostic factors (especially centre in multicentre trials), and is most important when sample sizes are small or prognostic factors strongly influence outcomes.
Inception cohorts recruit at a uniform early disease point to avoid survivor bias and lead-time bias, making them the preferred design for studying prognosis and natural history.
Low response rates in surveys introduce non-response bias when responders differ systematically from non-responders - response rates below 60% significantly threaten the validity of prevalence estimates.
Theoretical saturation - not a predetermined number - determines sample size in grounded theory; it is achieved when new data no longer contributes novel codes, categories, or theoretical insights to the emerging framework.
Snowball sampling recruits through participant referral networks, while maximum variation sampling deliberately seeks diverse perspectives - combining both strategies is effective for stigmatised populations where sampling frames are unavailable.
Ecological studies are best for rapid hypothesis generation using routinely collected aggregate data - they are especially appropriate when the exposure of interest is itself an area-level variable like deprivation or access to services.
The MAUP means that ecological associations depend on the geographical units used - results can change at different scales or with different boundary definitions, making robust multi-scale analysis essential.
Retrospective cohort studies use existing records to define cohorts historically and trace outcomes - they maintain temporal logic but are limited by the quality and completeness of available data.
Phase I trials are first-in-human studies in small numbers of healthy volunteers - they assess safety, tolerability, pharmacokinetics, and maximum tolerated dose; no efficacy data are collected at this stage.
Attrition bias is most concerning when dropout is systematic (MNAR) - always compare baseline characteristics of completers versus non-completers and use sensitivity analyses to explore the potential impact of missing data on conclusions.
The constant comparative method is the defining analytical procedure of grounded theory - it involves systematic comparison at every analytical level to develop categories inductively from data; it operates iteratively alongside theoretical sampling and memo-writing.
Statistical significance ≠ clinical significance - large samples can produce tiny p-values for clinically trivial effects; always report effect sizes and compare against minimum clinically important differences; p-values alone are insufficient for clinical decision-making.
Survivor bias occurs when non-responders or early failures are excluded from follow-up - it creates an artificially optimistic picture of long-term outcomes; all participants should be followed regardless of initial response.
Tick marks on Kaplan-Meier curves show censored observations - heavy or differential censoring between groups warrants investigation; the survival estimate becomes less reliable as the number at risk decreases, particularly in the right tail of the curve.
Poor reporting standard compliance hides methodological weaknesses and likely inflates published diagnostic accuracy estimates - the STARD checklist provides essential transparency, and readers should critically assess compliance when appraising diagnostic studies.
Semantic themes describe surface-level content while latent themes interpret underlying assumptions and frameworks - most analyses include both levels; being explicit about the analytical depth allows readers to assess whether interpretations are justified by the data.
The shape of the Kaplan-Meier curve reveals the pattern of event occurrence over time - a steep initial decline indicates high early hazard; in post-discharge suicide research, this consistently shows the highest risk in the first 1-3 months, supporting enhanced early follow-up protocols.
Kaplan-Meier survival probability at time t estimates the proportion remaining event-free, accounting for censoring - the complement gives the cumulative incidence; CIs widen as the number at risk decreases, and estimates become unreliable in the tail.
The Cox hazard ratio represents the instantaneous rate ratio at any time point, adjusted for other covariates - HR >1 indicates increased risk, HR <1 indicates protection; it assumes proportional hazards (constant ratio over time).
Hazard ratios are reciprocal when the comparison direction is reversed - HR = 0.40 (drug vs placebo) = 1/2.50 (placebo vs drug); always check the reference group; log HRs are symmetric around zero.
HR <1 indicates protection (reduced hazard), HR >1 indicates increased risk, HR = 1 indicates no effect - for continuous predictors, the HR represents the multiplicative change per unit increase; exponentiate the HR to calculate effects over multiple units.
Phase III trials are the definitive large-scale studies providing primary evidence for regulatory approval - they typically require 300-3000+ patients across multiple sites; regulatory agencies usually require two positive Phase III trials for new drug approval.
The DSMB independently monitors accumulating trial data for safety, efficacy, and futility - futility means the trial is unlikely to demonstrate benefit even if continued to full recruitment; adaptive designs allow informed modifications during the trial.
Competing risks analysis is needed when another event (death) prevents the outcome of interest - standard Kaplan-Meier treats death as censoring, implausibly assuming equal outcome risk, and typically overestimates cumulative incidence; Fine-Gray models properly handle competing risks.
The number-at-risk table is essential for assessing the reliability of Kaplan-Meier estimates - estimates based on few remaining participants are unreliable; always report and examine the number at risk, particularly at the tail of the curve where estimates are most uncertain.
Frailty models are Cox regression with random effects for clustered data - they account for unmeasured between-group heterogeneity; without them, standard errors are underestimated and p-values are too small when observations within clusters are correlated.
Enrichment (randomised withdrawal) designs increase power by studying only responders - they are efficient for demonstrating relapse prevention but limit generalisability to responders; the key question is whether initial response predicts long-term benefit.
Joint models simultaneously analyse longitudinal trajectories and time-to-event outcomes - they avoid bias from informative dropout, use the full biomarker trajectory rather than fixed values, and enable dynamic prediction with updated measurements.
Recurrent events models analyse all events per participant rather than just the first - they increase power and characterise total disease burden; Andersen-Gill, PWP, and WLW models differ in how they handle event ordering and within-patient correlation.
Cluster randomisation reduces effective sample size due to intra-cluster correlation - the design effect inflates the required sample size; even small ICCs substantially inflate sample sizes with large clusters; analyses must account for clustering to avoid underestimated standard errors.
Stepped-wedge designs introduce the intervention to all clusters sequentially in random order - each cluster serves as its own control; they are ideal when withholding the intervention would be unethical or simultaneous rollout is logistically impossible; time trends must be modelled in the analysis.
Platform trials use a shared control arm and adaptive rules to evaluate multiple treatments within one study - treatments can enter and exit the platform; this reduces patient numbers, accelerates evaluation, and maintains a single regulatory framework; Bayesian adaptive randomisation can allocate more patients to promising arms.
A systematic review is only as good as its search strategy - casting a wider net by including grey literature and registries helps catch studies that might otherwise slip through, reducing the impact of publication bias.
Two independent groups with normal continuous data = independent t-test; always check normality and variance equality first.
Same participants measured at three or more time points with normal data = repeated measures ANOVA; check sphericity with Mauchly's test first.
Paired data with non-normal distribution = Wilcoxon signed-rank test; it is the non-parametric mirror of the paired t-test.
Two categorical variables in a 2×2 table with adequate expected frequencies = chi-squared test; use Fisher's exact if expected counts are below 5.
Two continuous, normally distributed variables with a linear relationship = Pearson's r; use Spearman's when assumptions are violated.
Melatonin - first-line pharmacological for sleep in ASD; after ≥4 weeks sleep hygiene; start 2-3mg, 30-60 min before bed; Slenyto licensed for ASD in children ≥2; 50-80% of ASD children have sleep problems; abnormal melatonin synthesis in ASD; good safety profile; reduces sleep onset latency; improves total sleep time; sleep hygiene first.
Sensory hyper-reactivity - DSM-5 criterion for ASD; ~90% of ASD individuals affected; noise, light, texture, smell sensitivity; environmental adaptations essential; noise-cancelling headphones, quiet spaces, visual timetables; occupational therapy; sensory diets; reasonable adjustments under Equality Act 2010; hyper- and hypo-reactivity can co-exist; not hallucinations or malingering.
Echolalia, pronoun reversal, unusual prosody = social communication domain of ASD; echolalia can be immediate or delayed; pronoun reversal = deictic shifting difficulty; ~25-30% of ASD are minimally verbal; AAC systems (PECS, SGD); SALT core intervention; pragmatic language deficits; literal interpretation of language; prosody differences.
Growth faltering (down 2 centile lines) - consider drug holiday; reassess dose; switch to non-stimulant if persistent; ~1cm/year height velocity reduction; MTA study evidence; high-calorie evening snacks; take medication after breakfast; plot growth charts every 6 months; NICE NG87 monitoring; final adult height may be ~1-2cm less; balance growth vs untreated ADHD.
Annual medication review - NICE NG87; assess ongoing need, efficacy, side effects, growth, CV; trial periods off medication; drug holidays at developmental transitions; ~30-40% may manage without medication by late adolescence; ADHD evolves with development; comprehensive review (symptoms, function, growth, CV, comorbidities); involve child/family/school; not 'forever' for all.
New tics on methylphenidate - monitor 2-4 weeks (may be transient/coincidental); tics peak at 10-12 years; if persistent: reduce dose, switch to atomoxetine/guanfacine, or add clonidine; CBIT for tic management; no reliable causal link between stimulants and tics; balance ADHD control vs tic impact; guanfacine treats both; aripiprazole for severe tics; don't stop effective ADHD treatment prematurely.
Modified-release = avoid school-time dosing; if needed: written healthcare plan, parental consent, trained staff, locked storage (controlled drug); DfE guidance 2014; schools must support pupils with medical conditions; Equality Act 2010 - ADHD = disability; EHCP/SEN support if needed; reduce stigma with once-daily dosing; school staff do not prescribe.
ADHD + SLD comorbidity ~30-50%; treat both independently; ADHD medication improves attention, not SLD itself; 'rule of halves' for comorbidities; psychoeducational testing; EHCP for educational support; multimodal management; dyslexia needs specific teaching strategies; ADHD treatment helps engagement but not the learning difficulty; distinct aetiologies.
ADHD and driving - notify DVLA if it affects driving safety; medication does not prevent driving (may improve it); untreated ADHD = 1.5-2x accident risk; DVLA assesses individually; Group 2 licences stricter; stimulants reduce accident risk; counsel about driving safety in transition; adequate symptom control required; case-by-case assessment.
Risperidone monitoring in children - height/weight/BMI/waist, fasting glucose/lipids, prolactin, BP/HR, EPSE; at baseline, 3m, 6m, then annually; weight gain 2-4kg in 8 weeks; hyperprolactinaemia; RUPP trial - 69% response; start 0.25mg; combine with behavioural support; review regularly; shortest duration possible; metabolic syndrome risk.
ADHD heritability ~70-80%; one of most heritable psychiatric conditions; polygenic (DRD4, DAT1, SLC6A3); MZ twin concordance ~70-80%; gene-environment interaction; environmental factors: prenatal smoking/alcohol, prematurity, adversity; genetic overlap with ASD, depression; screen parents/siblings; parenting doesn't cause ADHD but modifies expression; rare CNVs in ~10-15%.
Predominantly inattentive ADHD = former ADD; more common in girls; diagnosed later; less disruptive = more easily missed; DSM-5 requires ≥6 inattention symptoms for ≥6 months; onset before age 12; two settings; significant impairment; girls may mask symptoms; gender bias in referral patterns.
Under 5s with ADHD - parent training first-line (NICE NG87); no medication licensed under 5; New Forest Parenting Programme designed for ADHD; environmental modifications essential; medication only if behavioural approaches insufficient; tiered approach based on age and severity; positive reinforcement over punishment.
ASD + ADHD - stimulants less effective (~49% vs 70-80% response); more side effects (irritability, stereotypies); start lower, titrate slower; RUPP trial evidence; DSM-5 allows dual diagnosis; ~30-50% of ASD have ADHD; atomoxetine and guanfacine alternatives; monitor behavioural deterioration; still offer stimulants - can significantly improve functioning; 25-50% of usual starting dose.
Pre-stimulant checks - height/weight on growth charts, HR/BP, cardiovascular history (personal + family), ECG if cardiac concerns; monitor every 6 months; growth chart monitoring critical; drug holidays if growth faltering; stimulants increase HR by 3-6 bpm, SBP by 2-4 mmHg; no increased sudden cardiac death risk without pre-existing conditions; NICE NG87.
Methylphenidate - decreased appetite most common (30-50%); monitor height/weight on growth charts; insomnia (adjust timing); mild CV effects (HR, BP); give after breakfast; high-calorie evening snacks; drug holidays may help growth; rebound irritability; ECG if family cardiac history; NICE NG87 monitoring protocol.
ASD sleep problems - multifactorial (circadian, sensory, anxiety, arousal); melatonin up to 10mg; weighted blankets; visual sleep schedules; assess for sleep apnoea, restless legs; review medications (stimulants, SSRIs); sensory-friendly bedroom; blackout curtains; white noise; bedtime fading; specialist sleep service referral; 50-80% of ASD children affected.
Methylphenidate - Schedule 2 controlled drug; specific prescribing requirements; max 30-day supply; specialist initiation then shared care with GP; does NOT cause addiction at therapeutic doses; modified-release = gradual dopamine increase (no euphoria); corrects DA deficit in ADHD brain; treated ADHD = lower substance misuse risk; handwritten/specific prescription requirements.
ASD management - no medication for core symptoms; NICE CG170; psychosocial interventions: ESDM, PECS, TEACCH, social skills groups; parent-mediated interventions; melatonin for sleep; risperidone/aripiprazole only for severe behavioural disturbance; SSRIs for anxiety; methylphenidate for ADHD comorbidity (may be less effective); structured teaching; visual supports.
Stimulant treatment for ADHD - protective against substance misuse (~50% risk reduction); untreated ADHD is the risk factor, not treatment; Wilens meta-analysis; therapeutic doses don't cause addiction; lisdexamfetamine = lower abuse potential (prodrug); monitor for diversion in adolescents; non-stimulants for established substance misuse; don't withhold treatment.
PDA - behavioural profile within ASD (Newson, 2003); not in DSM-5/ICD-11; extreme demand avoidance driven by anxiety; social strategies, surface sociability, mood lability; different from ODD (anxiety vs anger); management differs from typical ASD: reduce demands, flexibility, indirect requests, collaborative approach; standard behavioural management may escalate; PDA Society resources.
Lisdexamfetamine (Elvanse) - prodrug of dexamfetamine; cleaved by RBC enzymes; increases DA/NA release; ~13 hours duration; lower abuse potential (prodrug mechanism); NICE second-line after methylphenidate; start 30mg, max 70mg; can open capsule; less rebound than methylphenidate; same monitoring requirements; smoother pharmacokinetic profile.
Theory of mind deficit - difficulty understanding others' mental states; Sally-Anne test; affects English literature (character motivation), social interaction; maths/physics strengths (systematic reasoning); Baron-Cohen empathising-systemising theory; weak central coherence (Frith); executive dysfunction theory; teach ToM explicitly; social stories; complementary cognitive theories of ASD.
ADHD transition - plan from age 14; joint CAMHS/adult working; no treatment break; 60-70% of children continue to have adult symptoms; hyperactivity diminishes but inattention persists; reassess comorbidities; support self-management; service gaps are common; NICE NG87 transition pathway; named worker; post-transition follow-up essential.
ASD-BPD diagnostic overlap - common misdiagnosis in autistic women; emotional dysregulation in ASD = sensory/change triggers (vs interpersonal in BPD); identity confusion in ASD = masking effects; relationship difficulties = social communication deficits; self-harm may be sensory/regulatory; comprehensive developmental history essential; ASD = lifelong, BPD = adolescent onset; genuine comorbidity possible; camouflaging contributes to distress.
Guanfacine - selective α2A-agonist; strengthens PFC networks; Intuniv (ER) for ADHD; NICE NG87 after stimulants + atomoxetine; start 1mg, max 7mg; do NOT stop abruptly (rebound hypertension); sedation main side effect (transient); useful with comorbid tics/anxiety; monitor BP/HR; taper gradually to discontinue; less sedation than clonidine (α2A selective).
Atomoxetine - non-stimulant NRI; no abuse potential; 24-hour coverage; start 0.5mg/kg for 7 days then 1.2mg/kg; 4-6 weeks for full effect; MHRA warnings: hepatotoxicity and suicidal ideation; CYP2D6 metabolism; NICE NG87 third-line after methylphenidate and lisdexamfetamine; guanfacine is the other non-stimulant option.
ADOS-2 - gold standard observational assessment for ASD; semi-structured social presses; 5 modules by language level; rates social affect + RRBs; not diagnostic alone - combine with ADI-R, cognitive, language assessment; trained clinician required; 40-60 minutes; may miss camouflaging individuals; comparison score system; part of comprehensive MDT assessment.
Social skills groups - explicit teaching, role-play, video modelling, social stories; PEERS programme (strong evidence); LEGO therapy; include neurotypical peers; teach implicit rules explicitly; practice in safe environments; involve parents as coaches; balance skill teaching with identity acceptance; don't aim to 'normalise'; support social participation and wellbeing.
'Zombie' effect = over-medication; reduce dose or change formulation; optimal dose = best improvement with minimum side effects; preserved personality is essential; actively seek child's feedback; 'start low, go slow'; different release profiles suit different children; reassess dose regularly; effective treatment ≠ personality suppression; flexibility in dosing plan.
Stimulant rebound - worsening symptoms as medication wears off; manage with afternoon IR 'booster dose' or switch to longer-acting formulation; Concerta XL lasts ~12 hours; match formulation to daily needs; rebound ≠ medication failure; caused by abrupt dopamine/NA drop; various UK formulations with different release profiles; drug holidays an option.
Camouflaging - suppressing autistic traits to appear neurotypical; more common in females; causes anxiety, depression, burnout, suicidal ideation; contributes to delayed/missed diagnosis in girls; CAT-Q measures it; compensation + masking + assimilation; doesn't mean 'mild ASD'; creates identity confusion; unsustainable cognitive effort; clinical implications for assessment and support.
ADHD - 60-70% persist into adulthood; hyperactivity decreases, inattention persists; treatment improves outcomes; untreated risks: academic underachievement, substance misuse, accidents, relationship difficulties; protective factors: early treatment, family support, educational accommodations; MTA study - sustained optimal treatment matters; comorbid conduct disorder (not ADHD alone) predicts antisocial outcomes; transition planning essential.
ADHD = disability under Equality Act 2010; reasonable adjustments required; additional exam time, preferential seating, movement breaks; SEN support plan or EHCP; SEND Code of Practice 2015; JCQ exam access arrangements; SENCO coordinates school support; EHCP is legally binding; SEND Tribunal for appeals; 20-week EHCP process; both mainstream and special school options.
ADHD - symptoms in ≥2 settings required (DSM-5/ICD-11); onset before age 12; different impairment levels between settings are common; school demands may unmask symptoms; use multi-informant approach; Conners/Vanderbilt rating scales as adjuncts; exclude mimics (anxiety, sleep, hearing); specialist assessment required.
AAC for non-verbal ASD - PECS (6 phases), Makaton, speech-generating devices; does NOT prevent speech development; reduces frustration and challenging behaviour; NICE CG170 - SALT is core intervention; match to child's abilities; train communication partners; provide across all settings; early intervention essential; PECS based on ABA principles; tablet-based AAC apps available.
Stimming - serves regulatory, sensory, emotional functions; accept and accommodate; do not eliminate unless physically harmful; suppressing increases anxiety and mental health difficulties; offer alternatives if needed; neurodiversity-affirming approach; historically targeted by ABA (now criticised); modify environment, not the person; stimming ≠ intellectual disability; occurs across all ASD ability levels.
ADHD + anxiety (~25-30% comorbidity) - treating ADHD often improves anxiety; some get worse (activation side effect); MTA: medication + behavioural therapy best for comorbid anxiety; atomoxetine has anxiolytic properties; CBT adapted for ADHD; if anxiety worsens: reduce dose, add SSRI, or switch to atomoxetine; treat most impairing condition first; combined pharmacotherapy may be needed.
FBA before medication - identify function (escape, attention, tangible, sensory); PBS plan with proactive + reactive strategies; functional communication training (teach alternative to challenging behaviour); ABC recording; risperidone/aripiprazole only if PBS insufficient and behaviour severe; reducing demands if escape function identified; visual supports; predictable routines; never use restraint as first response.
ASD heritability ~80-90%; MZ concordance 60-90%; sibling recurrence 10-20%; polygenic + rare variants; >100 genes implicated; SHANK3, NRXN1 (synaptic genes); CNVs in 10-15% (CMA testing); syndromic causes: Fragile X, tuberous sclerosis, Rett, 22q11.2; genetic counselling recommended; cause identified in ~30-40% with current testing.
ADHD differentials - anxiety, adjustment disorder, trauma/ACEs, sleep disorders, attachment difficulties, learning difficulties, hearing/vision, thyroid; onset before age 12 required; 6-month history with specific trigger = needs careful evaluation; contextual factors matter; get previous school reports; ADHD is 70-80% heritable; pervasive across settings; comprehensive developmental history essential.
SSRIs in ASD - 'start low, go slow'; increased sensitivity to activation; 25-50% of usual starting dose; limited evidence base; target anxiety/OCD, not core ASD; monitor for agitation; consider liquid formulations; communication difficulties affect side-effect reporting; adapted CBT first-line for anxiety; fluoxetine or sertraline; NICE CG170.
Autistic regression - loss of language/social skills at 15-24 months; ~20-30% of ASD; differentiate from Landau-Kleffner (EEG), Rett syndrome (girls, hand-wringing), metabolic disorders; urgent referral; exclude hearing loss; may be more apparent than real (subtle earlier signs); now subsumed under ASD in DSM-5; regression does not define severity.
Methylphenidate and epilepsy - no absolute contraindication; no significant seizure risk increase at therapeutic doses; use with caution in well-controlled epilepsy; ADHD affects 20-40% of epilepsy patients; optimise anticonvulsants; monitor seizure frequency; drug interactions with phenytoin; treating ADHD improves adherence to anticonvulsants.
Social contagion in self-harm - real phenomenon; mechanisms: modelling, normalisation, reinforcement; school-based prevention: don't share graphic details; Papageno effect (protective responsible reporting) vs Werther effect (imitative); peer influence strongest in adolescence; contagion-influenced self-harm is still genuine; whole-school approaches; Samaritans media guidelines; individual + group support; social media as vector.
Treatment-resistant adolescent depression - reassess diagnosis; augmentation (lithium, aripiprazole); switch class with specialist supervision; alternative psychological therapies; ECT only for life-threatening, all-treatment-resistant (NICE - second opinion required); ECT response ~60-80%; very rarely used in <18s; lithium augmentation most evidence (adults); enhanced monitoring for non-first-line antidepressants; multidisciplinary decision.
DSED - indiscriminate friendliness with strangers; no caregiver preference; related to neglect/deprivation/institutional care; differs from RAD (inhibited/withdrawn); may persist after good placement; DSM-5 requires pathogenic care history; developmental age ≥9 months; ≥12 months duration; not explained by ADHD; important for looked-after children assessments.
Selective mutism - anxiety disorder; speaks at home, silent at school; ≥1 month; associated with social anxiety; 0.7-1% prevalence; onset before 5; graduated exposure (sliding-in technique); SSRIs for severe/treatment-resistant; never force speech; temperamental inhibition; bilingualism increases risk; classified as anxiety in DSM-5; CBT adapted for age.
School refusal - anxiety-based, stays home, parental knowledge, genuine distress; vs truancy - no anxiety, out of home, without parental knowledge; assess for separation anxiety, social anxiety, depression, bullying, ASD; graded return (exposure); CBT first-line; family intervention; school support; SSRIs if severe; don't punish anxiety-based avoidance; somatic symptoms common (stomach aches, nausea).
Patterson's coercion theory - negative reinforcement cycles; child escalation → parent capitulation → behaviour maintained; basis for parent management training; biopsychosocial model: genetic (MAOA, temperament) + psychological (cognitions, problem-solving) + social (family, peers, deprivation); protective factors: school, prosocial peers, warm adult relationship; parent training breaks the cycle.
PTSD in young children - traumatic play, regression, separation anxiety, nightmares, re-enactment; DSM-5 preschool subtype (≤6 years); domestic violence = ACE; TF-CBT adapted for age; child-parent psychotherapy (CPP); safeguarding essential; assess parent's mental health; ACE score ≥4 = elevated lifelong risk; NICE NG116; play-based therapy techniques; modified criteria for preschoolers.
CU traits - lack of remorse, callousness, shallow affect; DSM-5 'limited prosocial emotions' specifier; 30-50% of CD; reduced amygdala reactivity; heritability 40-70%; worse prognosis; standard parent training less effective; use reward-based, warmth-focused approaches; risk factor for ASPD; modify intervention, not abandon it; PCIT shows promise.
CBIT - first-line for tics; HRT (awareness + competing response + social support); 8 sessions/10 weeks; ~50-60% response rate; premonitory urge recognition; function-based assessment; relaxation; Piacentini et al.
DDP + PACE model - Playfulness, Acceptance, Curiosity, Empathy; Dan Hughes; attachment-focused; Bowlby's theory; Ainsworth's classifications (secure, avoidant, ambivalent, disorganised); Theraplay, VIG, Circle of Security also evidence-based; holding therapy NOT recommended (harmful); behaviour = communication of unmet needs; consistent, predictable caregiving; co-regulation before self-regulation.
Coprolalia - only 10-15% of Tourette's; most well-known but relatively uncommon; not required for diagnosis; related: copropraxia (5-10%), echolalia, palilalia; psychoeducation essential to reduce stigma; involuntary (not deliberate); CBIT/HRT can help; media portrayal is misleading; may improve over time; school education and adjustments needed; Tourettes Action resources.
Disorganised attachment - 'fright without solution'; caregiver = both safety and fear; strongest psychopathology predictor; 15% general population, 80% maltreated; Main & Hesse; parental unresolved trauma; AAI 'unresolved' classification; associated with dissociation, BPD traits, aggression; interventions: parent trauma therapy, reflective functioning, VIG, COS; freezing, contradictory approach-avoidance behaviours.
Conduct disorder - psychosocial first-line; medication for comorbidities (ADHD stimulants improve conduct symptoms by ~50%); risperidone for severe aggression only after psychosocial failure; NICE CG158; no medication licensed for CD specifically; short-term, lowest dose; monitor metabolic parameters; never substitute medication for psychosocial intervention; mood stabilisers not recommended.
Provisional tic disorder - tics <1 year; most common (15-20% of children); usually resolves spontaneously; watchful waiting + psychoeducation; don't draw attention to tics; reduce stress; if >1 year = persistent; if motor + vocal >1 year = Tourette's; CBIT if distressing; medication rarely needed; monitor for comorbidities; reassure parents.
Trichotillomania - OC-related disorder (DSM-5); tension-relief cycle; focused vs automatic pulling; HRT/CBIT first-line; ACT also effective; N-acetylcysteine has some evidence; assess for trichophagia; adolescent pattern more persistent than childhood; comorbid with other body-focused repetitive behaviours; classified with OCD, BDD, hoarding, excoriation; CSTC circuit involvement.
Negative reinforcement - both parties reinforced; Patterson's coercion cycle; child escalation removes demand (negative reinforcement); parent capitulation stops aversive behaviour (negative reinforcement); extinction burst expected when breaking the cycle; intermittent reinforcement = most resistant to change; follow through consistently; parent training breaks the cycle; calm clear instructions; reinforce compliance; manage parental emotions.
Multiple placement breakdowns - compound attachment insecurity; confirm internal working model that adults are unreliable; testing behaviour → rejection → further insecurity cycle; stability is priority; therapeutic parenting training essential; DDP/PACE/Theraplay; team around the child; transitions carefully managed; indiscriminate friendliness and controlling behaviour = attachment strategies; realistic expectations; time and consistency needed.
GAD in children - excessive worry across multiple topics; ≥6 months; prominent physical symptoms (stomach aches, headaches); reassurance-seeking; 3-5% prevalence; CBT first-line; parental accommodation maintains anxiety; SSRIs if CBT insufficient; commonly comorbid with depression and other anxiety disorders; may present to paediatrics with somatic symptoms; differentiate from specific anxiety disorders.
School exclusion - last resort; ensure ADHD optimally treated; reasonable adjustments (Equality Act 2010); SEN support/EHCP in place; behavioural strategies first; SEN/disability children = ~78% of permanent exclusions; parents can challenge; Timpson Review (2019); alternatives: managed moves, PRU, part-time timetable; function of behaviour; DfE guidance; ADHD = protected disability.
Treatment resistance - motivational interviewing (OARS); non-confrontational; transtheoretical model (pre-contemplation → contemplation); build alliance through genuine interest; work with family even if young person resists; strengths-based approach; hostile attribution bias in CD; relationship as therapy; flexible engagement (location, format); externalising blame is characteristic of CD; don't discharge - persist with engagement.
OCD vs tics - OCD: obsessions drive compulsions (anxiety reduction); tics: premonitory urge drives tic (sensory relief); 30-50% overlap with Tourette's; ERP for OCD, CBIT for tics; OCD compulsions are ritualistic and linked to thoughts; tics are simpler and sensory-driven; both involve CSTC circuits; treatment differs; tic-related OCD = 'just right' feelings, symmetry, touching.
Hostile attribution bias - interpreting ambiguous cues as hostile; key maintaining factor for reactive aggression; Crick & Dodge SIP model; CBT targets: social problem-solving, anger management, perspective-taking, cognitive restructuring; leads to reactive (not proactive) aggression; children with CD generate fewer prosocial solutions; evidence-based programmes: Anger Coping, Stop and Think; central to cognitive model of conduct disorder.
FT-AN/FBT - first-line for adolescent AN; Maudsley model; 3 phases (weight restoration, returning control, adolescent issues); parents take charge of feeding; externalise the illness; 6-12 months; Lock & Le Grange evidence; NICE NG69; if FT-AN not possible: AFT or CBT-ED; superior to individual therapy; parents as the best resource for recovery.
Safety plan (Stanley & Brown) - 6 steps: warning signs, internal coping, social contacts, people to help, professional/crisis contacts, making environment safe; collaborative and personalised; written in young person's words; no-harm contracts NOT recommended; means restriction is key; review regularly; share with family; accessible at all times; replaces outdated 'contracts'; evidence-based approach to crisis management.
Purging → hypokalaemia + metabolic alkalosis; loss of HCl and K+ in vomit; cardiac risk: arrhythmias, Torsades, cardiac arrest; ECG: flat T waves, U waves, prolonged QT; laxative abuse → metabolic acidosis; diuretic abuse → metabolic alkalosis; correct Mg2+ to fix resistant K+; monitor U&E and ECG regularly; most dangerous electrolyte: potassium; secondary hyperaldosteronism worsens K+ loss.
IPT-A - 4+1 focus areas: grief, role transitions, role disputes, interpersonal deficits + single-parent family; 12-16 sessions; 3 phases (initial, middle, termination); interpersonal inventory; Mufson adaptation; NICE CG28 recommends alongside CBT; particularly suited when depression linked to relationships; communication analysis, role-play; comparable evidence to CBT; Klerman/Weissman original model.
CAMHS inpatient admission - active suicidal ideation with plan, serious attempt, psychosis, safety concerns, severe self-neglect, failed community treatment, medical instability; specialist unit (not adult ward - legal requirement); maintain education; involve family; plan discharge early; least restrictive option; MHA 1983 if needed; most admissions are informal; Gillick competence; therapeutic milieu.
Cultural considerations in depression - somatic symptoms may predominate; stigma prevents disclosure; idioms of distress vary; family understanding may differ; culturally sensitive assessment essential; professional interpreters (not family); acculturation stress in minority ethnic youth; NICE recommends culturally adapted therapies; psychoeducation for families; somatisation common when psychological distress is stigmatised; collectivist vs individualist dynamics.
The community mental health framework transforms CMHTs by integrating them with primary care networks and voluntary sector - it addresses service gaps, particularly for people with personality disorders and complex needs who previously fell between service tiers.
Social inclusion ensures people with mental illness can participate fully in community life - it requires active promotion of employment, education, housing, and social participation, addressing stigma and discrimination alongside clinical treatment.
AOTs use integrated treatment for dual diagnosis - addressing mental illness and substance misuse simultaneously within the same team avoids the 'revolving door' of separate services and recognises the bidirectional interaction between conditions.
Section 136 suites are health-based places of safety for mental health crisis assessment - police stations should only be used in exceptional circumstances, detention lasts up to 24 hours (with possible 12-hour extension), and assessment must be by a doctor and AMHP.
CRT targets cognitive deficits in psychosis through structured exercises and strategy training - it is most effective when combined with other rehabilitation (e.g. IPS), and NICE recommends it as part of comprehensive psychosis care.
AOTs provide holistic practical support alongside clinical treatment - housing, benefits, employment, daily living skills, and social inclusion are addressed comprehensively, recognising that recovery requires attention to the full range of life domains.
Section 17 leave allows the RC to grant conditional leave from hospital to detained patients - it enables graduated discharge planning, can be for specified or indefinite periods, and the patient can be recalled if they deteriorate.
ICBs commission and plan healthcare services including mental health - they replaced CCGs under the Health and Care Act 2022, operate within Integrated Care Systems, and must meet the Mental Health Investment Standard ensuring adequate funding.
Service evaluation asks 'What does this service do?' - it differs from audit (which compares against standards) and research (which generates new knowledge through experimental methods), and typically requires only governance notification rather than ethics approval.
Parity of esteem - equal priority for mental and physical health - is a legal requirement under the Health and Social Care Act 2012, yet significant disparities persist, with mental health receiving approximately 13% of NHS expenditure despite accounting for 28% of disease burden.
QI uses rapid PDSA cycles for continuous improvement - it differs from traditional audit in its iterative, adaptive approach, drawing on manufacturing and systems science methodologies adapted for healthcare.
The Wessely Review recommended strengthening patient autonomy within the MHA - key proposals include advance choice documents, statutory care plans, limiting CTOs, raising the detention threshold, and addressing the racial disparities in detention rates.
SPC charts distinguish common cause (normal fluctuation) from special cause (genuine change) variation - this prevents overreacting to random variation or missing genuine changes, making them essential tools for quality improvement in healthcare.
Trauma-informed care is an organisational approach based on the four Rs - Realise, Recognise, Respond, Resist re-traumatisation - it asks 'What happened to you?' rather than 'What's wrong with you?' and creates safe, empowering service environments.
Social prescribing connects people to community resources (arts, exercise, volunteering, peer support) via link workers - it addresses social determinants of health, is embedded in the NHS Long Term Plan through primary care networks, and complements clinical treatment.
The CQC has a specific statutory MHA monitoring role - MHA Reviewer visits to detained patients, SOAD services for treatment safeguards, documentation review, complaints investigation, and annual monitoring reports on detention trends and patient experiences.
SOADs provide independent safeguards for detained patients' treatment - required after 3 months for medication (Section 58) and for any ECT in patients who refuse or lack capacity (Section 58A), managed by the CQC.
NCISH collects national data on suicides and homicides by mental health patients - its findings have directly influenced policy including post-discharge follow-up standards, ward safety improvements, and crisis service availability.
The Five Year Forward View for Mental Health (2016) set ambitious targets for expanding access, improving quality, and increasing funding - its recommendations were incorporated into the NHS Long Term Plan, though full implementation has been challenged by workforce shortages and COVID-19.
Service evaluations require trust-level governance approval but not research ethics approval - they assess how well a service meets its objectives using routine data, without randomisation or experimental manipulation, and the HRA decision tool helps confirm correct classification.
Out-of-area placements disrupt continuity of care, separate patients from families, complicate discharge, and increase costs - they result from local bed shortages and are targeted for elimination through improved gatekeeping, crisis alternatives, and bed management.
The CQC has graduated enforcement powers from requirement notices through warning notices, conditions, suspension, and cancellation to prosecution - actions are proportionate to the severity of concern, with the aim of driving improvement rather than simply punishing failure.
The Equality Act 2010 protects people with mental health conditions as a disability - services must make reasonable adjustments, and the public sector equality duty requires NHS organisations to actively eliminate discrimination and advance equality of opportunity.
Projects involving randomisation and aiming to generate new generalisable knowledge are classified as research requiring ethics approval - the HRA decision tool distinguishes research from audit and service evaluation based on methodology and purpose.
The NICE EIP package includes antipsychotic medication, CBTp, family intervention, IPS-supported employment/education, physical health monitoring, and substance misuse intervention - delivered by a specialist team for at least 3 years.
CRHT teams must recognise when home treatment has failed and escalate to admission - criteria include deteriorating risk, treatment non-response, unsafe home environment, and family unable to cope; MHA assessment should be considered if voluntary admission is refused.
CRHT teams should operate 24/7 to provide genuine crisis alternatives and effective gatekeeping - reduced hours undermine the model's effectiveness and lead to unnecessary out-of-hours admissions.
Liaison psychiatry assesses mental health crises in A&E and refers appropriate patients to CRHT for home treatment - this integrated pathway requires clear protocols, good communication, and 24/7 availability of both services.
Safety plans are collaborative, hierarchical, and personalised - they identify warning signs, coping strategies, contacts, and means restriction, and have replaced no-suicide contracts as the evidence-based approach to crisis management.
Care clustering groups patients into 21 needs-based clusters using the MHCT - it supports commissioning and resource allocation across three superclasses (non-psychotic, psychotic, organic), though the system has limitations in capturing individual complexity.
DIALOG is both an outcome measure and a therapeutic intervention - it covers 11 patient-rated life domains, structures clinical conversations around patient priorities, and DIALOG+ has been shown in RCTs to improve quality of life and reduce costs.
Audit standards should come from evidence-based guidelines (NICE), national audits (NCAP), or locally agreed evidence-based policies - they must be explicit, measurable, and achievable, with NICE guidelines providing the gold standard for most mental health audits.
CQC inspects against five key questions - Safe, Effective, Caring, Responsive, Well-led - with four-point ratings from Outstanding to Inadequate; mental health trusts receive ratings for each core service and an overall trust rating.
NHS England sets mental health strategy, standards, and commissioning frameworks - it monitors performance, manages the MHIS, directly commissions specialised services, and leads transformation programmes implementing the NHS Long Term Plan.
Co-production is an equal partnership between service users and providers - it goes beyond consultation to genuine shared power in designing, delivering, and evaluating services, and is a core principle of recovery-oriented mental health care.
The MHA Code of Practice's five guiding principles - least restrictive option, empowerment, respect and dignity, purpose and effectiveness, efficiency and equity - must inform all decisions under the Act, with departure requiring clear justification.
PSIRF moves from reactive incident-by-incident investigation to proactive, systems-based learning - trusts develop local Patient Safety Incident Response Plans focusing investigation resources where learning will have the greatest impact on care improvement.
EBCD uses filmed patient and staff experiences to identify improvement priorities - patients and staff work together as equal partners through co-design events, focusing on emotional 'touchpoints' that shape the experience of care.
The Mental Health Tribunal is an independent judicial body reviewing detention under the MHA - it comprises a judge, psychiatrist, and lay member, has the power to discharge patients, and must discharge if detention criteria are no longer met.
Family intervention reduces psychosis relapse by approximately 50% - NICE recommends at least 10 sessions over 3-12 months for all families in contact with the patient, though implementation rates remain disappointingly low.
Antipsychotic physical health monitoring includes weight/BMI, waist, BP, fasting glucose/HbA1c, lipids, prolactin, LFTs, renal function, FBC, and ECG - the Lester Resource provides a practical traffic light framework, but monitoring rates remain suboptimal despite the 15-20 year life expectancy gap.
Older adults deserve equitable access to crisis and home treatment - whether through age-inclusive CRHTs or dedicated older adults' crisis teams, with specific attention to physical health, frailty, polypharmacy, and safeguarding needs.
Personal recovery means building a meaningful life with or without symptoms - the CHIME framework (Connectedness, Hope, Identity, Meaning, Empowerment) captures the key processes, and recovery-oriented services prioritise outcomes that matter to patients.
When audit reveals a gap between practice and standard, implement targeted changes and re-audit - completing the cycle is essential; the NCAP consistently identifies suboptimal metabolic monitoring as a key area for improvement.
AMHPs coordinate MHA assessments and make detention applications - they exercise independent professional judgement, must consider less restrictive alternatives, and are not bound to follow doctors' recommendations automatically.
Recovery colleges offer co-produced educational courses on mental health and recovery - they position service users as students, promote empowerment and self-management, and are open to service users, carers, and staff on equal terms.
CMHTs provide assessment, treatment, and care coordination for adults with severe mental illness in the community - they are multidisciplinary teams sitting between primary and specialist secondary care, operating within the CPA framework.
CORE-OM measures psychological distress across wellbeing, problems/symptoms, functioning, and risk - it is a broad, pan-theoretical measure used widely in UK psychotherapy services, with a large normative database enabling benchmarking.
ACT showed strong US evidence for reducing hospitalisation and improving outcomes, but UK evidence is more mixed due to baseline differences in community provision - effectiveness depends on model fidelity, and integration into enhanced CMHTs risks diluting the key features that make assertive outreach effective.
Serious Incident investigations focus on systems learning, not individual blame - PSIRF promotes a just culture that distinguishes system failures from individual violations, uses root cause analysis, and develops actionable recommendations to prevent recurrence.
The AOT 'no discharge' policy maintains contact through periods of disengagement - recognising that non-engagement is a feature of illness rather than a reason for discharge, and that persistent, non-judgemental outreach eventually rebuilds trust and engagement.
First-episode psychosis prescribing follows 'start low, go slow' - first-episode patients are more sensitive to both effects and side effects, lower doses are often effective, and comprehensive metabolic monitoring from baseline is essential.
Mortality reviews systematically examine all deaths of patients known to mental health services - they identify modifiable factors and drive quality improvement, strengthened following the Mazars review (Southern Health) and supported by the NCISH national data.
The NHS Patient Safety Strategy has three aims - Insight (understanding safety through data), Involvement (equipping all stakeholders), and Improvement (designing safety programmes) - together creating a comprehensive, systems-based approach to reducing avoidable harm.
The audit cycle - set standards, collect data, compare, implement change, re-audit - is a continuous quality improvement process that measures practice against evidence-based guidelines; re-audit is essential to complete the cycle and demonstrate improvement.
CPA core elements are systematic assessment, written care plan, care coordinator allocation, and regular review - it coordinates NHS and social care for people with severe mental illness and complex needs, not private healthcare.
CRHT step-down requires structured handover to CMHT with overlap period, updated care plan, crisis plan, and medication information - the transition between services is a high-risk period requiring careful coordination.
Johnson et al. (2005) demonstrated that CRHT teams reduce hospital admissions - effectiveness depends on model fidelity including 24/7 operation, genuine gatekeeping, adequate staffing, and intensive home visiting.
When a home treatment patient is unexpectedly absent, the team must immediately contact the patient and known contacts, assess risk, and escalate to police involvement if risk is significant - proportionate response based on risk assessment is essential.
Section 117 aftercare is triggered by treatment sections (3, 37, 45A, 47, 48) - it is a joint duty of the ICB and local authority, must be provided free of charge (Stennett ruling), and continues until both bodies agree the person no longer needs aftercare.
Peer support workers use lived experience of mental illness to support others' recovery - they are employed, trained staff who provide hope, practical guidance, and unique perspectives that complement professional clinical roles.
The 'equally well' agenda addresses the 15-20 year life expectancy gap - EIP services play a crucial role by proactively assessing and managing physical health from the first episode, promoting healthy lifestyles, and ensuring equitable access to physical healthcare.
Efficacy demonstrates an intervention works under ideal conditions while effectiveness shows whether it works in real-world practice - the efficacy-effectiveness gap is a significant challenge for mental health services, addressed through fidelity monitoring, training, and routine outcome measurement.
ARMS individuals should be monitored by EIP services with CBT and symptom management but without routine antipsychotic medication - approximately 20-35% will transition to psychosis, making regular monitoring essential while avoiding unnecessary medication burden for the majority.
Crisis houses provide short-stay residential crisis care in a non-clinical, domestic-style environment - they offer an alternative to hospital admission with higher patient satisfaction, though they cannot manage detained patients or those requiring intensive medical supervision.
The CORE study identified that CRHT effectiveness depends on model fidelity - 24/7 operation, comprehensive MDT service, consistent gatekeeping, intensive home treatment, and early discharge facilitation are key components, and many teams operate below optimal fidelity.
CRHT admission decisions consider risk, social support, home safety, patient engagement, and available resources - living alone, recent overdose, and limited social support increase the threshold for home treatment, requiring enhanced safety planning if community management is chosen.
Advance statements document a person's treatment preferences when they have capacity - they must be considered in best interests decisions though are not legally binding like advance decisions; they are particularly valuable in relapsing-remitting conditions like bipolar disorder.
NHS 111 provides 24/7 mental health crisis triage and referral - it can transfer callers directly to local crisis services, complementing CRHT teams and other crisis resources as part of a comprehensive crisis care pathway.
Clinical governance encompasses audit, risk management, training, patient involvement, evidence-based practice, and information management - it is the framework for NHS accountability for quality improvement, introduced following high-profile service failures in the late 1990s.
PROMs are patient-completed measures of health outcomes - they include PHQ-9, GAD-7, CORE-OM, and QPR, capture the patient's perspective alongside clinician-rated measures, and are essential for person-centred outcome monitoring.
Aftercare is essential - highest relapse risk in first 3-6 months; comprehensive: relapse prevention therapy, mutual aid, community services, medication, employment/housing support; 40-60% relapse in first year; 5 years abstinence = significantly reduced risk; recovery capital: social, physical, human, cultural; multi-component approach; continuing care coordination; relapse risk decreases with time; sustained recovery is achievable.
Recovery capital - Granfield & Cloud; 4 domains: social, physical, human, cultural; internal + external resources for recovery; greater capital = better outcomes; assessment should identify strengths; treatment should build capital across domains; UKDPC framework; housing, employment, relationships, education all matter; predicts outcomes at treatment entry; recovery identity development; broader than just treatment; strengths-based approach.
First 2 weeks of methadone = highest death risk; accumulation before steady-state; long half-life (24-36h); start low (10-30mg), go slow (5-10mg every 3-5 days); supervised consumption essential; concurrent CNS depressants (benzodiazepines, alcohol) = dramatically increased risk; ~3000 drug deaths/year UK; assess before dosing; recently released prisoners also high risk; poly-drug use in most deaths.
GHB/GBL - GABA-B agonist; steep dose-response curve (narrow safety margin); rapid unconsciousness; date rape drug; severe physical dependence; life-threatening withdrawal (similar to DTs); onset 1-6 hours; benzodiazepines + baclofen for withdrawal; Class B drug; chemsex use; dosing every 2-4 hours in dependence; 'G'; GBL = prodrug of GHB; short duration; inpatient management for withdrawal.
Ketamine bladder - ulcerative cystitis; urothelial damage; contracted bladder; frequency, urgency, haematuria, pain; potentially irreversible; cessation essential for recovery; NMDA antagonist; K-hole (dissociation); biliary damage also common; Class B drug; paradoxical use as antidepressant; norketamine metabolite toxic; some recovery if early cessation; severe cases need surgery; affects 20-30% of regular users.
PCP - NMDA antagonist; dissociative; agitation, violence, analgesia, nystagmus (horizontal AND vertical); produces both positive AND negative schizophrenia symptoms; supports glutamate/NMDA hypofunction hypothesis; benzodiazepines for agitation; rhabdomyolysis risk; excited delirium; vertical nystagmus = clinical clue; avoid restraint; 'angel dust'; more complete model of schizophrenia than amphetamine (which only produces positive symptoms).
UK guidelines (2016) - ≤14 units/week for both sexes; spread over 3+ days; several drink-free days; no safe level; 1 unit = 10ml pure alcohol; pint of beer ≈ 2.3 units; glass of wine ≈ 2.3 units; binge = >6 units (women), >8 units (men); alcohol = Group 1 carcinogen; no alcohol in pregnancy; guidelines lowered from 21/14 in 2016.
Marchiafava-Bignami - corpus callosum demyelination; chronic alcohol + nutritional deficiency; cognitive decline, personality changes, seizures; interhemispheric disconnection; MRI: corpus callosum lesion; first described in Italian wine drinkers (1903); acute or chronic presentation; thiamine treatment; high mortality (acute form); rare; other rare conditions: CPM, pellagra, tobacco-alcohol amblyopia.
HCV - 50-80% prevalence in PWID; DAAs cure >95% in 8-12 weeks; treatment regardless of drug use status; pan-genotypic regimens available; UK elimination target 2030; NSPs reduce transmission; re-infection possible; dried blood spot testing; previous interferon treatment replaced; shared needles main UK transmission route; screen all PWID; treatment improves engagement with services.
Cannabis-induced psychosis - antipsychotic + cessation + monitoring; ~50% convert to primary psychotic disorder (highest conversion rate); resolves in days-weeks with cessation; monitor 3-5 years; distinguish from primary psychosis (>1 month symptoms despite abstinence = likely primary); continued use ↑ conversion risk; EIP involvement; psychoeducation essential; olanzapine/risperidone first-line; high-THC products highest risk.
Brief intervention - FRAMES model; 5-15 minutes; AUDIT 8-15; NNT ~8; highly cost-effective; any trained professional; NICE CG115; extended brief intervention for AUDIT 16-19; specialist referral for AUDIT ≥20; motivational interviewing style; empathic, non-judgemental; personalised feedback; Cochrane evidence; menu of options not prescriptive.
AA/TSF - Cochrane 2020 (Kelly): as effective as CBT/MET for abstinence; possibly superior for continuous abstinence; free and cost-effective; 12-step peer support; TSF = professionally delivered preparation for AA; Project MATCH, UKATT trials; criticism: spiritual component, powerlessness concept; SMART Recovery = secular alternative; complement professional treatment; mutual aid not medical treatment.
Withdrawal seizures - generalised tonic-clonic; 12-48 hours (peak 24h); brief, self-limiting; clusters of 2-6; previous seizures = strongest risk factor (kindling); mechanism: glutamate excess + GABA deficit; IV lorazepam for acute seizure; adequate benzodiazepine dosing prevents seizures; correct K+/Mg2+; investigate atypical features; status epilepticus in ~3%; long-term anticonvulsants not indicated for isolated withdrawal seizures.
Harm reduction - reduce harm without requiring abstinence; NSPs (reduce BBV transmission ~50-60%); BBV testing + hep B vaccination; take-home naloxone (Prenoxad, Nyxoid); safer injecting advice; OST reduces injecting and deaths; wound care; NICE PH52; ~1200 NSP sites UK; drug consumption rooms (international evidence); offer to all regardless of readiness to change; pragmatic public health approach.
Contingency management gives tangible reinforcement for verified positive behaviour change (negative drug tests); the strongest evidence is for stimulant dependence, where there is no effective pharmacotherapy; it is recommended by NICE CG51; it uses escalating rewards for consecutive clean tests with reset on relapse; voucher-based or prize-based; it addresses temporal discounting and is more effective than standard care.
Bad trip management - calm environment, reassurance ('talking down'), benzodiazepines if needed; self-limiting (psilocybin 4-6h, LSD 8-12h); antipsychotics second-line; avoid restraint; classic hallucinogens: low physiological toxicity; 5-HT2A agonists; rapid tolerance; no physical dependence; psilocybin therapeutic research (depression, end-of-life); set and setting crucial; HPPD rare complication.
SBNT - builds positive social network for recovery; identifies drinking vs recovery-supportive contacts; increases recovery contacts, reduces drinking contacts; involves network member in sessions; communication skills; UKATT trial (= MET effectiveness); NICE CG115 recommended; 8 sessions; social network theory basis; social environment influences drinking; practical and structured; developed for UKATT.
Alcoholic myopathy - most common skeletal muscle disease; ~40-60% of chronic drinkers; proximal weakness; type II fibre atrophy; direct alcohol toxicity; partially reversible with abstinence; acute form = rhabdomyolysis (CK, myoglobinuria, AKI risk); chronic form = insidious weakness; rehabilitation essential; adequate protein intake; recovery over 6-12 months; differentials: polymyositis, MND, myasthenia.
Cannabis withdrawal - DSM-5/ICD-11 recognised; ~47% of regular users; irritability, insomnia, appetite loss, anxiety, vivid dreams (REM rebound); onset 1-2 days, peak 2-6 days, resolves 1-3 weeks; not life-threatening; 9% of users develop dependence (17% adolescent-onset); treatment: CBT, MET, CM; no approved pharmacotherapy; THC lipophilicity → slow withdrawal; previously underrecognised; both psychological and physical symptoms.
Orange Book - Drug Misuse and Dependence: UK Guidelines on Clinical Management (2017); primary UK clinical guidance; covers assessment, prescribing, psychosocial, governance; OST for all opioid-dependent; supervised consumption ≥3 months; adequate dosing; harm reduction; specific populations; complements NICE guidelines; Dame Carol Black review (2020) recommended reinvestment; relevant to all clinicians; Department of Health publication; endorsed by Royal Colleges.
Pregnancy + alcohol withdrawal - supervised detox with benzodiazepines; uncontrolled withdrawal riskier than treated withdrawal; seizures can cause placental abruption; chlordiazepoxide/oxazepam; lowest dose, shortest duration; inpatient preferred; thiamine essential; multidisciplinary (addiction, obstetrics, neonatal, social services); achieve abstinence ASAP to reduce FASD risk; safeguarding pre-birth assessment; close obstetric monitoring (CTG, growth scans).
HPPD - persistent perceptual disturbances after hallucinogen use; visual trails, halos, geometric patterns, visual snow; full insight preserved; Type I (episodic) vs Type II (continuous); mechanism: 5-HT2A receptor changes; treatment: clonazepam (most evidence), lamotrigine; SSRIs may worsen; avoid cannabis, stress; gradual improvement in many; can occur after single use; distinguished from psychosis by preserved reality testing.
MI - Miller & Rollnick; collaborative, non-confrontational; RULE (Resist righting reflex, Understand, Listen, Empower); OARS (Open questions, Affirmations, Reflections, Summaries); stages of change model; MET = 4-session manualised MI (Project MATCH); elicit change talk; avoid arguing; decisional balance; effective for pre-contemplation/contemplation stages; applicable across all health behaviours.
Naltrexone - hepatotoxic at high doses; contraindicated in acute hepatitis/hepatic failure; ALT/AST >3× ULN = avoid; monitor LFTs baseline, 1 month, then 3-6 monthly; acamprosate = safer in liver disease (renal excretion); disulfiram also contraindicated in severe liver disease; nalmefene caution; this patient: acamprosate preferred; risk-benefit different in cirrhosis; 50mg standard dose = relatively low hepatotoxicity risk in normal liver.
Cocaine psychiatric effects - psychosis (paranoid, formication/'cocaine bugs'), depression (dopamine depletion), anxiety, cognitive impairment, aggression; phases: high → crash → withdrawal → extinction; sensitisation/kindling for psychosis; resolves in most within weeks of cessation; 5-10% persistent psychosis; no approved pharmacotherapy for cocaine dependence; CBT + contingency management = treatment; formication is pathognomonic.
Intoxicated + head injury - never attribute deterioration solely to alcohol; low threshold for CT head; repeat GCS as sobriety returns (if no improvement, suspect intracranial pathology); chronic alcohol leads to cerebral atrophy and subdural risk; coagulopathy increases bleeding risk; NICE NG232; monitor until sober; increased injury risk from falls/assaults; GCS unreliable in intoxication; complete assessment when sober.
Acamprosate - glutamate/NMDA modulation; restores excitatory-inhibitory balance; structurally similar to GABA; not hepatically metabolised (safe in liver disease); renal excretion (contraindicated in renal impairment); 666mg TDS; NNT ~9-12; start after abstinence achieved; COMBINE study suggested combination with naltrexone; half-life ~13 hours; steady-state 5-7 days; reduces protracted abstinence dysphoria.
Alcoholic neuropathy - distal, symmetrical, sensory predominant; stocking-and-glove distribution; direct neurotoxicity + nutritional deficiency (thiamine, B12, folate); affects 25-66% of chronic drinkers; treatment: abstinence, B vitamins, neuropathic pain management; axonal type on NCS; partial recovery possible; avoid opioids (cross-addiction); check HbA1c to exclude diabetes; gabapentin/pregabalin have abuse potential.
CIWA-Ar 12 = moderate withdrawal; benzodiazepines indicated; monitor every 2-4 hours; symptom-triggered regimens preferred (less benzodiazepine use, shorter treatment); <10 mild (may not need medication), 10-18 moderate (treat), >18 severe (escalate), >25 very severe (ICU); adjuncts: thiamine, fluids, electrolytes; escalate if worsening; calm environment; NICE CG115 supports both symptom-triggered and fixed-dose.
Alcohol + anxiety - bidirectional; self-medication (tension reduction) → neuroadaptation → worsened anxiety; reassess after 3-4 weeks abstinence; 20-40% comorbidity; SSRIs for independent anxiety (not benzodiazepines - cross-dependence risk); CBT effective; GABA downregulation + glutamate upregulation = chronic anxiety; withdrawal anxiety very common; most improves with abstinence; panic, social anxiety, PTSD, GAD all comorbid.
Mephedrone - synthetic cathinone; monoamine releaser (DA, NA, 5-HT); stimulant + empathogen; Class B since 2010; previously legal ('plant food'); effects similar to amphetamine + MDMA; complications: agitation, paranoia, hyperthermia, serotonin syndrome; benzodiazepines for toxicity (no beta-blockers); hyponatraemia risk; MDPV and alpha-PVP are more potent cathinones; related to khat plant cathinone.
Crack = freebase cocaine (smoked); onset seconds vs minutes (powder); shorter duration (5-15 min vs 30-60); more intense high and crash; faster addiction development; route determines addictiveness (smoking > snorting); crack lung; no approved pharmacotherapy; CBT + contingency management; Class A; pharmacologically identical to powder; social consequences more severe; rapid cycling drives compulsive use.
Long-term OST - reduces mortality ~50%; evidence supports indefinite treatment; premature cessation → 60-80% relapse; treatment duration = strongest predictor of success; view as chronic disease management; both methadone and buprenorphine; Orange Book, NICE, WHO support; returning to treatment always an option; benefits only maintained while on treatment; patient-led decisions about tapering.
Take-home methadone criteria - ≥3 months supervised; consistent attendance; negative drug tests; stable dose and social circumstances; no alcohol misuse; safe storage (locked cabinet); methadone = most common childhood poisoning death drug; graduated increase; return to supervised if instability; Orange Book guidance; risk assessment including children; diversion risk assessment; regular ongoing review.
Cannabis-induced psychosis → ~50% convert to schizophrenia-spectrum within 3-4 years; highest conversion of any substance; EIP follow-up essential; cessation reduces but doesn't eliminate risk; suggests underlying vulnerability; EU-GEI: daily high-potency = 5× psychosis risk; 12% population attributable fraction; amphetamine ~20-30% conversion; family history increases risk; prevention through reducing cannabis use; all should receive EIP assessment.
Controlled drinking - valid goal for hazardous/harmful (non-dependent); abstinence recommended for dependence; harm reduction accepted when abstinence not achievable; NICE CG115 offers choice for harmful drinkers; Sobell controversy; nalmefene supports harm reduction approach; reducing consumption reduces harm; recovery broader than just abstinence; moderation achievable for many non-dependent drinkers; pragmatic approach.
Amphetamine psychosis - key evidence for dopamine hypothesis; indistinguishable from paranoid schizophrenia; mesolimbic DA excess → positive symptoms; Seeman correlation (D2 affinity = potency); PET: elevated presynaptic DA synthesis; limitations: doesn't explain negative/cognitive symptoms; glutamate also involved; updated hypothesis: mesolimbic excess + mesocortical deficit; supports but doesn't fully explain schizophrenia.
Chemsex - methamphetamine, mephedrone, GHB/GBL; facilitates/enhances sex; predominantly MSM; risks: HIV/STI (condomless sex, multiple partners), GHB overdose, dependence, psychosis, sexual assault; integrated services needed; PrEP; routine enquiry in MSM assessments; GHB narrow therapeutic window; sessions can last days; non-judgemental approach; addresses substance use + sexual health + mental health intersection.
Supervised consumption - prevents stockpiling, diversion, childhood ingestion; pharmacist assesses intoxication/withdrawal before dispensing; daily for ≥3 months; not punishment - safety; Orange Book guidance; pharmacist documents observation; withhold if intoxicated; methadone = most common childhood poisoning drug; acknowledge patient burden; graduated to take-home when stable; applies to both methadone and buprenorphine.
Pre-contemplation - doesn't recognise problem; MI to raise awareness; stages: pre-contemplation → contemplation → preparation → action → maintenance (± relapse); match intervention to stage; confrontation at pre-contemplation = resistance; relapse is normal, not failure; Prochaska & DiClemente transtheoretical model; applies to all behaviour change; may cycle multiple times; personalised feedback raises awareness.
Cocaine intoxication - benzodiazepines first-line; NO beta-blockers (unopposed alpha stimulation → paradoxical hypertension); active cooling for hyperthermia; cardiac monitoring (MI risk in young patients - vasospasm); sodium channel blockade → arrhythmias; blocks DA/NA/5-HT reuptake; cocaine chest pain: GTN + aspirin + benzodiazepines (not beta-blockers); rhabdomyolysis, seizures, psychosis as complications.
Buprenorphine - wait for objective withdrawal (usually ≥6-12h after heroin, 24-72h after methadone); COWS ≥12 before starting; the partial agonist displaces full agonists and can precipitate withdrawal; titrate to 12-16mg maintenance; Suboxone (with naloxone) deters injection; Buvidal is a long-acting depot; ceiling effect on respiratory depression makes it safer than methadone in overdose.
Lofexidine - alpha-2 agonist; reduces noradrenergic hyperactivity from locus coeruleus; treats sweating, tachycardia, restlessness; UK-licensed for opioid withdrawal; not an opioid; 0.2mg BD to max 2.4mg/day; monitor BP (hypotension risk); additional symptomatic Rx: loperamide, NSAIDs, metoclopramide; less effective than OST taper; 7-10 day course then taper; clonidine similar but not UK-licensed.
Prescription opioid dependence - 5-26% develop OUD; codeine most commonly misused prescription opioid in UK; OTC availability a problem; CYP2D6 (ultra-rapid metabolisers at risk); secondary harms: paracetamol hepatotoxicity, ibuprofen GI bleeding; management: gradual reduction, buprenorphine, MDT pain management; NICE NG193 against opioids for chronic primary pain; deprescribing initiatives; hidden problem in community.
Khat - Catha edulis; contains cathinone + cathine; natural stimulant (like mild amphetamine); chewed leaves; East African/Yemeni communities; Class C since 2014 (controversial); health risks: dental, cardiovascular, insomnia, rare psychosis; social concerns: isolation, financial strain; cathinone = template for synthetic cathinones; cultural sensitivity in assessment; dental disease most common health effect.
N2O - inactivates B12 (oxidises cobalt); SCDC (posterior columns + lateral corticospinal tracts); serum B12 may be normal (inactive forms measured); IM hydroxocobalamin treatment (not cyanocobalamin); loss of proprioception/vibration, sensory ataxia, UMN signs; Lhermitte's sign; partial recovery with treatment; young people - canisters; Psychoactive Substances Act 2016; vegetarians/vegans at higher risk; cessation essential.
E-cigarettes - ~95% less harmful than smoking (OHID); NICE NG209 recommends as cessation option; not risk-free but much safer than smoking; nicotine addictive but not the main cause of disease (combustion = harm); EVALI linked to THC/vitamin E acetate, not standard UK nicotine vapes; concern about youth uptake; aim to eventually stop vaping too; varenicline = most effective single agent; UK harm reduction approach; NRT also important.
Methadone taper - gradual (weeks-months); 5-10mg reductions at higher doses; 2.5mg at lower doses; final stages slowest and most challenging; patient-led pace; psychosocial stability before tapering; concurrent therapy; may switch to buprenorphine for final stage; pause/increase if intolerable; stable long-term OST is a positive outcome; forced tapers have worse outcomes; proportionally larger impact at lower doses.
Illicit use on methadone → likely inadequate dose; therapeutic range 60-120mg; increase dose if needed; never punitively discharge (↑ death risk); review psychosocial factors; treatment retention = strongest predictor of success; regular review and drug testing; non-punitive approach; OST reduces mortality, BBV, crime; consider switching to buprenorphine; assess end-of-dose withdrawal; address concurrent substance use.
QTc >500ms = Torsades de Pointes risk; methadone prolongs QTc dose-dependently; reduce dose or switch to buprenorphine (no QTc effect); correct K+/Mg2+; stop other QTc-prolonging drugs; baseline ECG before starting; repeat at stabilisation and if >100mg; risk factors: female, electrolytes, co-prescribing, cardiac disease; buprenorphine preferred for cardiac risk patients; cardiology review if QTc >500ms.
Post-prison release - 7-8× overdose death risk in first 2 weeks; loss of tolerance is the key mechanism; take-home naloxone before release (NICE NG52, ACMD); pre-release overdose training; continuity of OST through release; community treatment within 24-48 hours; first week = highest risk period; tolerance loss occurs in days-weeks; same dose now lethal; ~3000-4000 drug deaths/year UK; pre-release planning essential.
PSA 2016 - blanket ban on supply of psychoactive substances; exemptions: alcohol, tobacco, caffeine, food, medicines; personal possession NOT an offence (except prisons); supplements Misuse of Drugs Act 1971; addressed NPS/'legal highs' proliferation; closed head shops; supply/production/import offences; dark web sales continue; does not replace MDA drug classifications; Class A/B/C still governed by MDA 1971.
ICD-11 dependence - 3 core features: impaired control, increasing priority, physiological features (tolerance/withdrawal); ≥12 months (or 1 month if continuous); simplified from ICD-10 (6 criteria); DSM-5: AUD mild/moderate/severe (11 symptoms); Edwards and Gross (1976) original syndrome description; narrowing, salience, tolerance, withdrawal, relief drinking, compulsion, reinstatement; ICD-11 applies to all substances.
Buvidal - weekly (8-32mg SC) or monthly (64-128mg SC); eliminates daily dispensing; reduces diversion; improves adherence; normalises daily life; NICE TA731; injection by trained professional; injection site reactions main side effect; ideal for stable patients, adherence issues, rural areas; cost-effective considering reduced supervision; subcutaneous depot formation; reduces stigma of daily pharmacy visits.
, well-validated for identifying alcohol dependence.
Korsakoff syndrome - chronic amnestic; anterograde amnesia, confabulation; mammillary body + thalamic damage; untreated Wernicke's → Korsakoff's (~80%); ~25% recover significantly; ~50% no improvement; largely irreversible; prevention: thiamine supplementation; oral thiamine poorly absorbed in drinkers; parenteral Pabrinex for at-risk; long-term supported accommodation needed; MRI: mammillary body atrophy.
AUDIT - 10-item WHO tool; score 8-15 hazardous, 16-19 harmful, ≥20 possible dependence; AUDIT-C (3 items) for quick screening; CAGE (Cut-Annoyed-Guilty-Eye-opener) for dependence; NICE CG115 recommends AUDIT; brief interventions for scores 8-15; covers consumption, dependence symptoms, and harmful consequences; FAST for busy settings; SASQ as first-step screen.
Cannabis psychiatric risks - psychosis (2-4× risk, dose-dependent), amotivational syndrome, depression, anxiety, dependence (9% users, 17% adolescent-onset), cognitive impairment; Dunedin study (4× risk by age 26); high-THC/low-CBD = highest risk; COMT Val/Val + cannabis = 10× psychosis risk; EU-GEI study; adolescent brain particularly vulnerable; 'two-hit' model; endocannabinoid system in neurodevelopment.
Fentanyl - 50-100× more potent than morphine; microgram doses lethal; contaminates heroin unpredictably; hotspots in batches; may need higher/repeated naloxone doses; carfentanil ~10,000× morphine; fentanyl analogues; standard drug screens may miss it; North American crisis; increasing UK presence; drug checking services; fentanyl test strips; re-narcotisation risk after naloxone.
Binge drinking = >6 units (women) / >8 units (men) in single session; significant acute risks (injuries, poisoning, violence, holiday heart) and chronic risks (liver, brain, cancer); ~30% of A&E attendances involve alcohol; AUDIT 18 = harmful drinking; weekday abstinence doesn't eliminate risk; most common pattern in young adults; holiday heart syndrome (binge → AF); 50% of alcohol A&E attendances from binge pattern.
Classical conditioning - cues (pub, companions, emotions) become conditioned stimuli triggering craving; cue exposure therapy (extinction); Marlatt & Gordon relapse prevention model; high-risk situations; stimulus control; urge surfing (mindfulness); seemingly irrelevant decisions; MBRP; cognitive restructuring of permission-giving thoughts; craving is time-limited (peaks and passes).
Evidence-based therapies - MET, CBT, BCT, SBNT, TSF, CM; NICE CG115 recommends choice; Project MATCH: MET = CBT = TSF; UKATT: MET = SBNT (MET more cost-effective); Dodo Bird verdict - relationship may matter more than modality; offer alongside pharmacotherapy; matching effects exist; therapeutic alliance important; multiple formats (individual, group, couples).
Section 37 - hospital order; alternative to prison; convicted of imprisonable offence; 2 medical recommendations; equivalent to Section 3; 6 months, renewable; Section 41 - restriction order (Crown Court); no time limit; Secretary of State consent for discharge/leave/transfer; conditional discharge possible; public protection; Section 45A - hybrid order; Section 35 - remand for report; Section 36 - remand for treatment; Section 38 - interim hospital order.
Section 47 - transfer direction (sentenced prisoners); Section 49 - restriction direction (usually combined); Secretary of State authorises; 2 medical reports (1 Section 12); MHCS processes; remission to prison when treated; Section 48/49 - remand prisoners; recommended 14-day transfer (often delayed); equivalent to Section 37/41; cannot discharge without SoS consent; medium/high security hospitals; prison psychiatrist identifies need.
Section 4 - emergency assessment admission; 72 hours; ONE medical recommendation + AMHP; urgent necessity; convert to Section 2 ASAP; rarely used; genuine emergency only; not for convenience; preferably a doctor who knows patient; detention only (not treatment); overuse = system problem; 28-day Section 2 period starts from Section 4 admission; out-of-hours emergency situations.
IMHA - statutory advocacy; qualifying patients (detained, CTO, guardianship); rights: understand rights, participate in decisions, access information; right to private visits; right to access records (with consent or in patient's benefit); hospital must inform patients; commissioned by local authorities; statutory powers under MHA; distinct from general advocacy; supports patient's voice; can attend CPA meetings; can make complaints; does not make treatment decisions; does not replace NR.
Advance decisions and MHA - ECT: advance decisions specifically recognised (Section 58A, cannot override); medication: MHA Part IV takes precedence (advance decisions noted but can be overridden); unique safeguard for ECT; capacitous patient can refuse ECT even when detained; SOAD cannot override valid advance decision for ECT; MCA advance decision requirements apply; no automatic expiry; Code of Practice: respect ADs as far as possible; Section 28 MCA - MHA takes precedence for mental disorder treatment; attorney/deputy can also refuse ECT.
Section 135(1) - private premises; warrant from magistrate; AMHP application; police + AMHP + doctor enter; mental disorder + ill-treated/neglected/unable to care; Section 135(2) - retake AWOL patients; Section 136 - public places; no warrant; police power; 24 hours (both); place of safety; key difference: private vs public; force entry if necessary; 2017 amendments aligned durations; evidence to magistrate required for 135.
Civil MHA patients (Sections 2, 3, 4, 5, guardianship, CTO) - CAN vote; Section 47/49 (transferred from prison) - CANNOT vote (sentenced prisoners); Section 37 (hospital order) - CAN vote (not imprisoned); hospitals must facilitate; postal/proxy vote; register at home or hospital address; fundamental democratic right; Code of Practice; Electoral Commission guidance; Hirst v UK (2005) ECHR on prisoner voting; voting right retained in civil detention.
Forensic recovery - personal (CHIME) + forensic (offending insight, risk reduction, victim empathy, responsibility, non-offending identity); double stigma; long detention; institutionalisation; recovery-oriented practice: involvement, meaningful activities, hope, strengths-based; Good Lives Model (Ward & Stewart); responsible risk-taking; individual and non-linear; tension between security and recovery; gradual community reintegration; education/employment preparation.
Victim Contact Scheme - Probation Service; serious offences (12+ months sentence or hospital order); VLO assigned; information about key events; representations on conditions (exclusion zones, non-contact); Domestic Violence, Crime and Victims Act 2004; Victims' Code (2021) - 12 rights; VPS (Victim Personal Statement); victim's voice in risk management; no veto over discharge; MHCS for restricted patients; statutory right; dignity and respect.
Ethnic disparities - Black people 4× more likely detained, 10× more likely CTO; overrepresented in seclusion, restraint; CQC annual reports document; Wessely Review highlighted; PCREF introduced; multiple explanatory factors: institutional racism, socioeconomic deprivation, cultural barriers, diagnostic bias, police pathways, lack of trust; not yet resolved; proposed MHA reforms address; diagnostic bias (schizophrenia overdiagnosis); lack of culturally appropriate services; persistent and intersecting inequalities.
Therapeutic jurisprudence - Wexler & Winick; law as social force; therapeutic/anti-therapeutic consequences; promote well-being; don't subordinate justice/due process; mental health courts; drug courts; problem-solving courts; judge as therapeutic agent; forensic psychiatry application: how legal processes affect patients; advocacy for therapeutic legal processes; interdisciplinary; restorative justice; balancing treatment and justice; developed 1990s.
Section 63 - treatment for mental disorder without consent from start; 3-month rule → Section 58 (consent or SOAD); SOAD appointed by CQC; consults 2 professionals; Section 58A - ECT safeguards (capacity, advance decisions); Section 57 - neurosurgery (consent AND SOAD); Section 62 - emergency treatment; Form T3 (SOAD certificate); 3-month clock starts at first administration; Part IV only applies to detained patients.
Capacity ≠ automatic discharge from MHA; MHA independent of MCA; appeal routes: Tribunal, RC, hospital managers, NR (Section 23); capacity is relevant factor but not determinative; Winterwerp criteria (ECHR Article 5); Code of Practice: take capacity into account; formal process required; ongoing legal debate; patient may still meet Section 3 criteria despite having capacity; relapse risk may justify continued detention.
Fire-setting classification - revenge (most common), excitement, crime concealment, profit, political, attention-seeking, mental disorder-related; pyromania is rare (1-3%); DSM-5 impulse control disorder; previous fire-setting = strongest recidivism predictor; risk factors: PD, substance use, LD, isolation; treatment: FIPP, CBT, DBT; Rix (1994), Canter & Fritzon (1998) models; both adults and children; arson = most common index offence for women in secure hospitals.
DVLA notification - patient's legal duty; psychiatric conditions: psychosis, mania, severe depression/anxiety, substance misuse, PD with behavioural disturbance; doctor advises and documents; if patient refuses → may breach confidentiality (GMC guidance); Group 1 vs Group 2 (stricter); medication sedation effects; DVLA medical adviser decides; 'Assessing fitness to drive' guide; acute psychosis/mania = must not drive; substance misuse = licence revoked until stability demonstrated.
OPD pathway - jointly commissioned (NHS England + HMPPS); high-risk offenders with PD; replaced DSPD programme; screening, formulation, PIPEs (prison), treatment (hospital), community services; formulation-driven (not diagnosis-driven); PIPEs = psychologically informed environments; workforce development; identification → formulation → progression → resettlement; PD is treatable; consistency and containment; staff training essential.
Risk assessment evolution - static 'dangerousness' → dynamic 'risk'; SPJ approach (HCR-20V3); static factors (history) + dynamic factors (current state) + protective factors (SAPROF); risk fluctuates; guides management not just prediction; first generation (clinical) → second (actuarial) → third (SPJ) → fourth (protective factors); dynamic factors are treatment targets; risk management plans; acknowledges uncertainty; individual not just group level.
CQC - monitors MHA operation; visits detained patients; appoints SOADs; investigates complaints; publishes annual reports; replaced MHAC (2009); reviews compulsory powers use; monitors restrictive practices; ethnic monitoring (disproportionate use concern); checks rights information; does not discharge patients (Tribunal's role); independent regulatory body; annual 'Monitoring the Mental Health Act' report; Section 58/58A compliance.
SAPROF - Structured Assessment of Protective Factors; de Vogel et al.
Wessely Review (2018) - modernise MHA; nominated person (replaces NR); advance choice documents (statutory); therapeutic benefit criterion; address racial disparities (Black patients 4× more likely detained); CTO reform; four principles: choice, least restriction, therapeutic benefit, individual; Mental Health Bill (2022+); LD/autism: should not be sole grounds; strengthened advocacy; patient's wishes central; ongoing parliamentary process.
Mullen et al.
LD in forensic settings - fitness to plead may be affected; diminished responsibility possible; capacity assessments essential; adapted treatment programmes (simplified, visual, longer); Equality Act reasonable adjustments; overrepresented in CJS (5-10% prison population); appropriate adult; intermediaries; sexual offending (lack of education, consent understanding); fire-setting (impulsivity); proposed MHA reform: LD alone insufficient for detention; vulnerability at every CJS stage.
Section 17 - RC grants leave; escorted or unescorted; grounds or community; hours to extended periods; conditions can be attached; revocable at any time; restricted patients need SoS consent; AWOL if fails to return; essential for rehabilitation; not discharge (patient remains detained); Section 19 for transfer; extended leave vs CTO debate; gradual reintegration; risk assessment tool; RC cannot delegate.
Detained patient - retains physical health consent rights; MHA = mental disorder treatment only; capacitous patient consents → common law; capacitous patient refuses physical treatment → respect refusal (usually); lacks capacity → MCA (best interests); anorexia NG feeding → may be MHA Part IV (B v Croydon); Section 145 broad definition of 'treatment for mental disorder'; detention ≠ loss of all decision-making rights; separate frameworks for mental and physical health.
S136 = police power; public place only (S135 for private dwellings); 24 hours (12-hour extension); health-based place of safety preferred, never police station for under-18s; assessment by doctor + AMHP; consult mental health professional before use where practicable.
Automatism - involuntary act (no conscious control); sane (external cause) = acquittal; insane (internal cause) = NGRI; sleepwalking = insane (R v Burgess); epilepsy = insane (R v Sullivan); insulin hypoglycaemia = sane; total loss of control required; not self-induced; internal/external distinction controversial; common law defence; complete defence; different consequences (acquittal vs NGRI); medical vs legal classification tension.
M'Naghten Rules (1843) - insanity defence; defect of reason, from disease of the mind; not know nature/quality of act OR not know it was wrong; NGRI verdict; burden on defence (balance of probabilities); 'wrong' = legally wrong (R v Windle); rarely used (~30/year); complete defence; disposals: hospital order, supervision, absolute discharge; 'disease of the mind' = legal concept (broad); distinct from diminished responsibility (partial defence).
Diminished responsibility → voluntary manslaughter → discretionary sentencing; options: hospital order (±restrictions), imprisonment (including life), suspended sentence, community order; murder = mandatory life; key benefit of DR defence; Section 45A hybrid order also available; judge considers: disorder severity, public risk, treatment availability; Section 47/49 transfer from prison possible; individualised sentencing; psychiatric evidence important.
Loss of control (CJA 2009, Sections 54-56) - replaced provocation; 3 requirements: loss of self-control + qualifying trigger (fear of violence OR extremely grave circumstances) + reasonable person test; sexual infidelity excluded; need not be sudden (addresses domestic abuse 'slow burn'); revenge excluded; murder → manslaughter; forensic psychiatrists provide evidence; 'battered person syndrome' relevant; R v Duffy no longer applies; partial defence (same as diminished responsibility).
PCL-R - Hare; 20 items; scored 0-40; cut-off ≥25 (UK) / ≥30 (N America); Factor 1: interpersonal/affective (callousness, grandiosity, lack of empathy); Factor 2: antisocial lifestyle (impulsivity, criminal versatility); strong predictor of recidivism; not sole basis for decisions; ethical concerns (death penalty); cultural bias potential; PCL-SV (screening); PCL-YV (youth); 4-facet model; clinician-rated (file review + interview).
Sexual violence risk tools - Static-99/2002 (actuarial), RSVP (SPJ), SVR-20 (SPJ), Stable/Acute 2007 (dynamic); combine static + dynamic for best assessment; base rate ~5-15% over 5 years (detected); risk factors: multiple victims, male victims, deviant interests, psychopathy; SOTP withdrawn 2017 (Mews evaluation); current: BNM+, Kaizen; Stable-2007 identifies treatment targets; Acute-2007 for crisis management.
Fire-setting recidivism risk factors - previous fire-setting (strongest); PD (ASPD); substance use; fire interest/fascination; social isolation; unemployment; LD; poor emotional regulation; childhood fire-setting; childhood abuse; criminal versatility; no specific validated actuarial tool; SPJ approach with fire-specific factors; Four Factor Fire Scales (Ó Ciardha); treatment: reduce fire interest, emotional regulation, coping strategies, social inclusion; fire-setting cycle insight.
Criminal liability - actus reus + mens rea; mental disorder may negate mens rea or found defences; insanity (M'Naghten), diminished responsibility, automatism; mens rea: intention, recklessness, knowledge; strict liability = no mens rea needed (rare); intoxication: specific intent offences (can negate); basic intent offences (generally cannot - Majewski); forensic psychiatrist provides expert evidence; does not determine guilt; murder = intention to kill/GBH.
Fire-setting and LD - overrepresented; limited understanding of consequences; impulsivity; communication difficulties (fire as expression); curiosity/fascination without malice; attention-seeking; adapted treatment needed (simplified, visual, concrete); FIP-MO; distinguish: curiosity, communicative, impulsive, antisocial fire-setting; NFIRS for fire interest assessment; develop alternative coping and communication; fire safety education; shorter sessions; role-play effective; not punishment-focused.
Dual diagnosis - comorbid mental disorder + substance use; 50-80% of forensic patients; increases violence, non-adherence, relapse, re-offending; integrated treatment (same team, simultaneously); MI, CBT, CM, medication, relapse prevention; substance use = strongest modifiable violence risk factor; cannabis most common; bidirectional relationship; NICE recommends integrated approach; criminogenic need; avoid 'falling between services'; social interventions (housing, employment).
Responsivity principle - match treatment to individual; general: CBT most effective; specific: adapt for gender, ethnicity, age, motivation, cognition, personality, mental health, literacy; RNR model (Andrews & Bonta); adhering to all 3 principles reduces recidivism ~30-35%; violating principles may increase recidivism; LD: simplified materials; cultural adaptation; psychopathy: structured behavioural; women: gender-responsive; motivational interviewing for low motivation; individualised approach essential.
Future challenges - ethnic disparities (PCREF); MHA reform (Wessely, Mental Health Bill); community forensic development; trauma-informed care; gender-responsive services; LD/ASD reform; prison transfer delays (14-day target); digital health; public protection vs patient rights/recovery; pharmacogenomics; neuroscience; co-production; outcome measurement; workforce; health-justice interface; recovery-oriented practice; personalised care.
Canter & Fritzon (1998) - 2-dimensional arson model; target: person vs object; motivation: instrumental vs expressive; 4 types: instrumental-person (revenge), instrumental-object (fraud), expressive-person (cry for help), expressive-object (emotional release/fascination); guides treatment; women overrepresented in forensic fire-setting; BPD, trauma, emotional dysregulation common in female fire-setters; FIPP, FIP-MO treatment programmes; arson = most common female index offence in secure care.
Section 12(2) - special experience in mental disorder; at least 1 of 2 doctors for MHA assessment; training + experience required; reapproval every 5 years; primarily psychiatrists and experienced GPs; personal examination required (within 5 days of each other); second doctor ideally knows patient; Approved Clinician (AC) - RC role for non-medical professionals; Section 12 training covers MHA, MCA, risk, human rights; delegated by Secretary of State to HEE.
ASD and criminal responsibility - recognised medical condition for DR; fitness to plead considerations; sentencing mitigation; theory of mind difficulties; cognitive rigidity; sensory overload in court; most autistic individuals don't offend; offending patterns: stalking, internet offences, fire-setting; misunderstanding of social rules; proposed MHA reform: ASD alone insufficient for detention; assess understanding of wrongfulness; interaction with co-occurring conditions.
Criminogenic needs - dynamic risk factors linked to offending; Central Eight (Andrews & Bonta): Big Four (antisocial cognition, associates, personality, history) + Moderate Four (family, employment, substance use, recreation); RNR model: Risk (match intensity to risk), Need (target criminogenic needs), Responsivity (match to learning style); CBT most effective; adherence to all 3 principles reduces recidivism ~30-35%; high-risk benefit most from intensive intervention; low-risk may be harmed by intensive intervention.
VRAG - actuarial tool; Quinsey et al.
Mental disorder and mens rea - theoretically can negate; in practice: insanity and diminished responsibility are the routes; intention, recklessness, knowledge = mens rea; specific intent offences more susceptible; English law channels through established defences; complete acquittal concern (no supervision); Law Commission reform considered; forensic psychiatrist provides evidence on mental state and intent; doesn't determine legal outcome; mental disorder does not automatically negate.
Stalking legislation - Protection from Harassment Act 1997; Protection of Freedoms Act 2012 (specific stalking offences: Section 2A, Section 4A); Stalking Protection Act 2019 (SPOs - pre-conviction); restraining orders; MASIP (multi-agency); S-DASH (police screening); SAM, SRP (specialist assessment); maximum 10 years (Section 4A); National Stalking Helpline; Paladin; following, contacting, monitoring, loitering = examples; both criminal and civil remedies.
Section 2 - assessment; 28 days; not renewable; uncertain diagnosis/first admission; appeal within 14 days; Section 3 - treatment; 6 months; renewable; established diagnosis + treatment plan; appeal once per period; both: 2 medical recommendations + AMHP application; nearest relative can object to Section 3; Section 12 approved doctor required; appropriate treatment must be available (Section 3).
Infanticide Act 1938 - mother kills child under 12 months; balance of mind disturbed from birth/lactation; treated as manslaughter; discretionary sentencing; postpartum psychosis ~1-2/1000 births; onset within 2 weeks; psychiatric emergency; mother and baby unit admission; typically non-custodial sentences; broadly interpreted; prosecution can charge or defence can raise; specific to biological mother; avoids mandatory life sentence.
Both insanity and diminished responsibility may apply; insanity = complete defence (NGRI, indefinite detention); diminished responsibility = partial defence (murder → manslaughter, discretionary sentencing); choice depends on legal strategy; both require expert psychiatric evidence; psychotic delusion may satisfy both tests; M'Naghten: didn't know nature/quality OR didn't know it was wrong; DR: abnormality + recognised medical condition + substantial impairment + explains killing; prosecution can raise insanity.
Tribunal and restricted patients - SHALL discharge if criteria not met; absolute or conditional discharge; conditional = conditions in community + recall power; deferred if arrangements not ready; accommodation delays common; victim liaison scheme (representations, not veto); Secretary of State can also discharge/recall; mandatory discharge if criteria not satisfied; does not require symptom-free; Probation victim contact scheme; exclusion zones and non-contact conditions.
Section 35 - remand to hospital for report; court order (Crown or Magistrates'); 28 days (renewable to 12 weeks); 1 medical recommendation (Section 12 approved); bed within 7 days; does not authorise treatment; Section 36 - remand for treatment (Crown Court only, 2 doctors, authorises treatment); Section 38 - interim hospital order (up to 12 months, authorises treatment); accused or convicted but not sentenced; purpose = prepare psychiatric report.
Retrospective assessment - inherently uncertain; not present at the time; multiple sources needed (defendant, witnesses, records, CCTV, phone data); malingering must be considered; distinguish mental disorder from intoxication/personality; express probability not certainty; relevant to multiple defences; expert witness duty to court (independence); acknowledge limitations; time affects memory; forensic evidence important; body-worn camera footage increasingly useful.
Boundary management - recognise the dynamic; clinical supervision essential; team formulation (not blame); consistent team responses (prevent splitting); boundaries = therapeutic; document; counter-transference awareness; BPD patients recreate attachment patterns; minor to major violations (spectrum); sexual contact with detained patient = criminal offence; staff wellbeing: supervision, reflective practice; 'See Think Act'; warmth with boundaries; don't punish relational behaviour.
Court report - comprehensive: qualifications, sources, personal/psychiatric/forensic/substance history, MSE, retrospective MSE, diagnosis, formulation, relationship to offence, fitness to plead, risk assessment, treatment, disposal recommendations; duty to court; independent opinion; plain language; Criminal Procedure Rules Part 19; distinguish fact from opinion; acknowledge limitations; list all sources; Section 37/41, 45A, 47/49 disposal options.
MHA - capacity does not prevent detention; MHA and MCA operate independently; capacity is relevant but not determinative; MHA takes precedence for mental disorder treatment (Section 28 MCA); Rabone v Pennine Care (2012) - Article 2 operational duty; the Code of Practice (2015) treats capacity as an 'important factor'; ECHR Article 5 permits detention of 'unsound mind'; BPD patients can be detained; separate legal frameworks.
Restraint - last resort; de-escalation first; least restrictive, shortest time; proportionate and necessary; document fully; post-incident debrief; Code of Practice 2015; NICE NG10; Restraint Reduction Network Standards (2019); prone restraint risk (positional asphyxia); rapid tranquillisation: lorazepam or haloperidol+promethazine; seclusion guidance; trauma-informed approach; regular audit; reduction strategies; trained staff only.
Three high-security hospitals - Broadmoor (Berkshire), Rampton (Nottinghamshire), Ashworth (Merseyside); ~750 beds total; grave and immediate danger to public; hospitals not prisons; medium security = RSUs (~3,500 beds); low security (~2,500 beds); community forensic services; stepdown pathway; The State Hospital (Carstairs, Scotland); conditions of special security; MHA detention; treatment-focused; formerly 'special hospitals'.
HCR-20V3 - 20 items; 3 scales: Historical (10 static), Clinical (5 dynamic), Risk Management (5 future); SPJ approach; no numerical score; final judgement by clinician (low/moderate/high); most widely used violence risk tool; validated internationally; guides risk management not just prediction; dynamic factors targetable by treatment; comprehensive and transparent; Douglas et al.
ASPD treatment - NICE CG77; group-based CBT programmes (reasoning and rehabilitation, enhanced thinking skills); MBT; therapeutic communities (Grendon prison); focus on offending, substance use, interpersonal functioning; no specific medication; realistic goals; structured programmes; long-term engagement; DSPD programme (discontinued); medication for comorbidities only; challenging but not untreatable; peer challenge effective; motivational approaches.
Self-harm in forensic settings - formulation-driven approach; understand function (emotional regulation, communication, self-punishment); DBT skills (distress tolerance, emotional regulation); collaborative safety planning; reduce restrictive interventions (can escalate self-harm); address trauma; NICE CG133; not punishment or ignoring; compassionate and consistent responses; staff support essential; power dynamics; relational security; 'See Think Act'; not 'attention-seeking'; function-specific interventions.
Acute stress and criminal responsibility - loss of control (qualifying trigger + loss of self-control), diminished responsibility (recognised medical condition + substantial impairment), automatism (dissociative state + total loss of control); battered person syndrome / coercive control; PTSD in veterans; retrospective assessment needed; malingering consideration; acute stress reaction, PTSD = recognised medical conditions; relationship between stress and actions must be established; both acute and chronic stress relevant.
SAM - Kropp, Hart, Lyon (2008); SPJ tool for stalking; 3 domains: Nature of Stalking (10), Perpetrator Risk (10), Victim Vulnerability (10); unique in assessing victim factors; risk conclusions: nature, severity, imminence, frequency, likelihood; generates management recommendations; SRP (alternative tool); S-DASH (police screening); multi-agency management (MASIP); restraining orders/SPOs; perpetrator treatment based on motivation; victim safety planning central.
Young people forensic assessment - age of criminal responsibility 10 (England/Wales); neurodevelopmental immaturity (PFC not mature until mid-20s); welfare principle (Children Act); SAVRY (youth SPJ tool); appropriate adult; high prevalence: ADHD 25-30%, SLCN ~60%, mental health disorders 30-50%; ACEs; looked-after children overrepresented; diversion preferred; labelling effect; youth justice: prevent offending + promote welfare; adapted tools and approaches.
Trauma in forensic populations - 50-90% experienced childhood adversity; ACEs dose-response relationship; trauma-informed care (TIC): safety, trust, collaboration, empowerment; 'what happened to you?'; victim-perpetrator overlap; restricive practices can re-traumatise; trauma underlies self-harm, aggression, substance use, relationship difficulties; EMDR, trauma-focused CBT, NET available; timing of trauma processing important; organisational approach not just individual therapy; cultural sensitivity.
Domestic Abuse Act 2021 - statutory definition (physical, emotional, coercive/controlling, economic, sexual); Domestic Abuse Commissioner; aggravating factor in sentencing; no cross-examination by abuser; coercive control extended to post-separation; DAPOs; children as victims (not just witnesses); Serious Crime Act 2015 (Section 76 - coercive control offence); relevant to DR and loss of control defences; complex PTSD in victims; economic abuse included for first time.
Meaningful occupation - structure/routine (reduces risk); builds community living skills; non-offending identity; improves mental health/self-esteem; addresses criminogenic needs (education, employment); graded ward → community activities; OT central role; MOHO framework; IPS supported employment; creative therapies; education; vocational rehabilitation; employment = strong protective factor; unstructured time = risk factor; recovery-oriented; holistic rehabilitation.
Gender-responsive forensic care - different pathways (victimisation, coerced offending, survival); 80-90% trauma; more self-harm, less interpersonal violence; Bloom, Owen, Covington principles; relational approaches; integrated substance use/trauma/MH treatment; mother-baby units; childcare responsibilities; parenting programmes; domestic violence; staff gender dynamics; socioeconomic needs; safety, respect, dignity; women as minority in forensic settings.
Section 45A hybrid order - prison sentence + hospital direction + limitation direction; Crown Court only; prison sentence runs regardless; remission to prison if treatment complete; notional Section 37 if sentence expires; originally for PD; now broader use; R v Vowles (2015): consider in every case; advantages: fixed sentence, safety net; disadvantages: may hinder engagement; combines punishment and treatment; equivalent to Section 41 restrictions while in hospital.
Relational security - 3rd dimension (+ physical, procedural); staff knowledge of patients; 'See Think Act' framework; observation, understanding, action; therapeutic relationships; boundaries; applies at all security levels; failures linked to serious incidents; team communication essential; knowing patients' histories, triggers, patterns; translating knowledge into care; Department of Health 2010; most nuanced and important dimension; requires training and reflective practice.
CTO (Section 17A) - community living with conditions; recall to hospital (up to 72 hours); cannot force medication in community; conditions: residence, appointments, medication compliance; RC + AMHP required; must have been Section 3; revocation = readmission under Section 3; renewal: 6 months then annually; OCTET trial: no significant benefit; controversial (coercion, ethnic disparities); Part IV applies only when recalled.
MHA - mental disorder; compulsory detention/treatment; does not require lack of capacity; MCA - all decisions for people lacking capacity; 5 principles (presumption of capacity, support, unwise decisions, best interests, least restrictive); Section 28 - MHA takes precedence; DoLS/LPS for non-MHA deprivation of liberty; Cheshire West (2014); separate but overlapping; MHA for mental disorder treatment; MCA for everything else when capacity lacking.
Psychopathy and violence - PCL-R is strongest single predictor; 3-4× recidivism rate; Factor 2 (antisocial lifestyle) + combination strongest prediction; Factor 1 predicts instrumental violence; psychopathy + sexual deviance = strongest sexual recidivism predictor; poorer treatment response; risk reduction focus; avoid unstructured group therapy; cognitive-behavioural approaches; supervision essential; debate about treatment increasing risk; instrumental > reactive violence in psychopaths.
Institutionalisation - long-term institutional stay; loss of independence, skills, identity, motivation, social connections; Goffman's 'total institution' (1961); barrier to rehabilitation; resistance to discharge; learned helplessness; mitigation: maintain skills, social connections, autonomy, graduated community access, normalisation; recovery-oriented practice counters institutionalisation; occurs in hospitals and prisons; develops gradually; difficult to reverse; occupational therapy essential; individualised care.
Desistance - gradual process of ceasing offending; identity transformation (non-offending self); social bonds (employment, relationships); internal (motivation, values) + external (opportunities); Giordano: cognitive transformation (openness, hooks, replacement self, reassessment); Maruna: redemption scripts; Sampson & Laub: turning points; gradual, not sudden; support identity, social inclusion, hope; strengths-based; recovery capital; imprisonment can hinder desistance; forensic services should support desistance process.
nfvPPA - effortful, non-fluent, agrammatic speech + apraxia of speech + preserved single-word comprehension; left posterior frontoinsular atrophy; usually tau pathology; speech therapy is key intervention; distinguish from svPPA (fluent but empty) and logopenic PPA (word-finding pauses).
Confabulation - fabricated memories without intent to deceive; fills gaps caused by amnesia; two types: provoked (common, on questioning) and spontaneous (unprompted, frontal dysfunction); Korsakoff's features: anterograde amnesia + confabulation + temporal confusion; only ~25% show partial recovery.
who someone is (semantic memory for people), prosopagnosia specifically refers to the perceptual inability to recognise the face itself.
CST - strongest evidence among non-pharmacological interventions for cognition in dementia; 14 sessions over 7 weeks + maintenance; comparable to ChEI benefit; NICE recommends for mild-moderate dementia; group-based, stimulating, person-centred; can be combined with medication; cost-effective.
End-stage dementia - sensitively discuss prognosis and goals of care; check for ADRT/LPA; best interests decision-making under MCA 2005; balance benefit vs burden of treatment; comfort-focused care; support family with anticipatory grief; dementia is a terminal condition deserving palliative approach.
Lithium augmentation for elderly TRD - best evidence; lower target levels (0.4-0.6 mmol/L); increased toxicity risk (reduced renal clearance); watch for interactions (NSAIDs, ACEi, diuretics); more frequent monitoring; dehydration is a major risk in elderly; alternative: aripiprazole augmentation.
Unwise ≠ incapacity (MCA Principle 3); capacity is decision-specific and time-specific; same threshold regardless of consequences; if all four criteria are met, the refusal must be respected even if it leads to death; document thoroughly; consider second opinion for high-stakes decisions.
Asymptomatic bacteriuria in elderly - up to 50% in care homes; positive urine may be coincidental; over-attribution of delirium to UTI is a common error; systematically exclude all causes; look for genuine urinary symptoms; investigate thoroughly even with positive urinalysis; treat if symptomatic UTI confirmed.
Cotard's syndrome - nihilistic delusions ('organs rotting, I am dead'); most common in severe elderly psychotic depression; constitutes a psychiatric emergency when refusing food/drink; ECT is the treatment of choice (80-90% response rate); MHA Section 58A or MCA may be needed if lacking capacity.
Z-drugs in elderly - same risks as benzodiazepines (falls 1.5x, confusion, dependence); start at half dose (zopiclone 3.75mg); use for shortest possible time; CBT-I is the gold standard for chronic insomnia; melatonin PR is a safer alternative for ≥55; NICE: non-pharmacological approaches first.
Venlafaxine = highest discontinuation syndrome risk; taper gradually (37.5mg every 1-2 weeks); 'brain zaps' are characteristic; in elderly, discontinuation can mimic delirium or relapse; cross-taper is usually recommended; liquid formulations for very slow tapers; NEVER switch to MAOIs without adequate washout.
AChEI side effects = cholinergic excess - diarrhoea, nausea, cramps, bradycardia (SLUD); donepezil, rivastigmine, galantamine all share these; manage with dose reduction, slower titration, or switch to rivastigmine patch; check ECG; avoid concurrent anticholinergics; contraindicated in sick sinus syndrome.
Rivastigmine - strongest evidence for PDD (EXPRESS trial); dual AChE + BuChE inhibition; patch formulation reduces GI side effects; NICE NG71 recommends for mild-moderate PDD; may improve cognition, hallucinations, apathy; cholinergic deficit is greater in PDD than AD; may mildly worsen tremor transiently.
Sundowning - evening worsening of BPSD; affects 20-45% of dementia patients; circadian disruption, melatonin reduction, fatigue; first-line is non-pharmacological (routine, lighting, activity, unmet needs); bright light therapy; validation not confrontation; trazodone before antipsychotics; exclude delirium.
MCA 2005 functional test - 4 elements (understand, retain, weigh, communicate); failure in ANY ONE = lacks capacity; decision-specific and time-specific; 5 statutory principles; unwise decisions ≠ incapacity; best interests if lacking capacity; least restrictive option; support before concluding incapacity.
NMS tetrad - hyperthermia, rigidity, altered consciousness, autonomic instability; CK markedly elevated; mortality 10-20%; stop antipsychotic immediately; dantrolene + bromocriptine; ICU care; haloperidol > atypicals for risk; dementia increases risk; wait 2 weeks before cautious rechallenge with different agent.
NPI - gold standard for BPSD assessment; 12 domains including delusions, hallucinations, agitation, depression, anxiety, apathy, disinhibition; rates frequency, severity, and carer distress; variants: NPI-Q (brief), NPI-NH (care homes); Cornell Scale for depression in dementia; CMAI for agitation specifically.
Delirium on dementia - acute onset (hours-days), fluctuating, reversible if cause treated; dementia is biggest risk factor; 4AT screening tool; investigate UTI, pneumonia, medications; NICE CG103; treat cause, not symptoms; avoid antipsychotics if possible; affects ~50% hospitalised elderly with dementia; pyrexia = infection until proven otherwise.
SSRIs - best evidence for compulsive/repetitive behaviours in bvFTD; serotonergic deficit in FTD; cholinesterase inhibitors not recommended (may worsen symptoms); trazodone for agitation; bvFTD: disinhibition, apathy, loss of empathy, compulsive behaviours; ~30-40% genetic; Rascovsky criteria for diagnosis.
AD median survival 4-8 years (variable 2-20+); NICE NG97 - named coordinator, care plan, advance care planning, carer support; Alzheimer's Society support; admiral nurses for carers; OT, SALT, continence services; LPA and financial planning while capacity preserved; Care Act 2014 for social care; support throughout disease trajectory.
MHA 1983 can override capacitous refusal for mental disorder treatment - distinct from MCA which requires lack of capacity; Section 3 criteria: mental disorder, necessity, appropriate treatment available; Section 63 authorises treatment without consent; Wessely Review recommended greater role for capacity in MHA decisions.
Semantic variant PPA - fluent but empty speech, impaired naming and single-word comprehension, preserved repetition; anterior temporal atrophy (left > right); part of FTD spectrum; distinguish from logopenic PPA (AD pathology) by preserved repetition and impaired comprehension.
ChEI side effects are peripheral cholinergic - GI (nausea, diarrhoea), muscular (cramps), cardiac (bradycardia); manage by slow titration, taking with food, or switching to rivastigmine patches; tolerance often develops; monitor ECG for bradycardia; contraindicated in sick sinus syndrome.
FTLD pathology - tau (~40%), TDP-43 (~50%), FUS (~5-10%); genetic predictors: MAPT → tau, GRN → TDP-43, C9orf72 → TDP-43; C9orf72 is the most common genetic cause of both FTD and ALS; FTD-ALS overlap in ~15% of cases; no disease-modifying treatment available.
PSEN1 is the most common cause of familial EOFAD (30-70% of autosomal dominant cases); PSEN2 and APP are rarer causes; all three affect amyloid processing; APOE ε4 is a risk factor for sporadic late-onset AD; Down syndrome → AD due to extra APP gene on chromosome 21.
Person-centred dementia care (Kitwood) - respond to emotional content, not factual; validate feelings; understand behaviour as communication; avoid repeated distressing reality orientation; reminiscence and redirection are therapeutic; Dementia Care Mapping evaluates care quality.
DLB autonomic dysfunction - caused by α-synuclein in autonomic ganglia and brainstem; orthostatic hypotension, constipation, urinary problems; manage hypotension with fludrocortisone or midodrine; avoid anticholinergics for urinary symptoms (use mirabegron); increases falls risk.
ChEIs contraindicated in sick sinus syndrome and significant heart block - enhanced vagal tone causes bradycardia; check ECG before starting; caution with concurrent beta-blockers, calcium channel blockers, digoxin; ask about syncope/falls/dizziness; monitor heart rate.
Iatrogenic CJD - transmitted through medical procedures; cadaveric growth hormone and dura mater grafts are key routes; incubation up to 40+ years; prions resist standard sterilisation; practice discontinued in 1985; new cases still emerging from historical exposures; strict decontamination protocols essential.
Delirium vs dementia - delirium: acute, fluctuating, impaired attention, altered consciousness; dementia: insidious, progressive, impaired memory, clear consciousness; delirium ON dementia occurs in 25-50% - always consider delirium in any acute change; CAM is the recommended screening tool.
Elder abuse signs - unexplained injuries, neglect, financial exploitation, anxiety around specific individuals; refer under Care Act 2014 Section 42; six types: physical, psychological, sexual, financial, neglect, discriminatory; Making Safeguarding Personal places the person at the centre; clinicians must report.
Organisational abuse - systemic care failures (pressure sores, dehydration, weight loss, understaffing); distinct from individual abuse; refer to local authority + notify CQC; Care Act 2014 recognises this category; warning signs: multiple incidents, high staff turnover, poor CQC ratings; whistleblowing protections for staff.
Amitriptyline = ACB score 3 (highest anticholinergic burden); cumulative ACB ≥3 increases delirium and cognitive decline risk; avoid in elderly: TCAs, oxybutynin, chlorphenamine, promethazine; use ACB Scale for medication review; deprescribing anticholinergics prevents delirium and preserves cognition.
Memantine - NMDA antagonist; add to AChEI in severe AD or use as monotherapy; blocks glutamate excitotoxicity; start 5mg, titrate to 20mg; DOMINO trial supports combination therapy; NICE recommends for severe AD; mild side-effect profile; do not combine two AChEIs.
Diazepam + codeine = high falls risk (dual CNS depression); diazepam half-life 36-200 hours in elderly (accumulation); Beers flags long-acting benzodiazepines; prefer lorazepam if benzodiazepine essential; SSRIs/CBT for anxiety; review opioid need; STOPP/START flags concurrent benzodiazepine-opioid prescribing.
DNACPR - clinical decision by senior clinician; LPA holder consulted but cannot demand futile CPR; Tracey ruling - must involve patient/family; DNACPR ≠ withdrawal of all treatment; ReSPECT for holistic planning; LPA allows refusal not demand of treatment; document and review regularly.
Risperidone for BPSD - start 0.25mg BD, titrate slowly to max 1mg BD; licensed for max 6 weeks; only antipsychotic licensed for BPSD in UK; 3x stroke risk, 1.5-1.7x mortality; discuss risks with family; review within 6 weeks; document rationale; plan discontinuation.
Anticipatory prescribing - 'just in case' box for end of life; morphine SC (pain/dyspnoea), midazolam SC (agitation/seizures), glycopyrronium SC (secretions), levomepromazine SC (nausea); prescribed PRN; NICE NG31; avoids delays; syringe driver for continuous symptom control; train staff in SC technique; regular reassessment.
Getting lost in familiar environments reflects visuospatial/topographical orientation impairment - parietal and retrosplenial cortex affected; posterior cortical atrophy is an AD variant with early visuospatial loss; safety implications: driving fitness, supervision, tracking devices; a marker of progressing disease severity.
Wernicke's triad - confusion, ataxia, ophthalmoplegia (only 10-30% have all three); give Pabrinex IV BEFORE glucose; ~80% progress to Korsakoff's if untreated; pathology: mammillary bodies, medial thalamus; Korsakoff's: irreversible anterograde amnesia + confabulation.
Delirium - acute onset, fluctuating course, disturbed attention, visual hallucinations, identifiable precipitant; affects 20-30% of medical inpatients, up to 50% postoperative; independently increases mortality 2-3x; treat the CAUSE, not just the symptoms.
Mirtazapine (NaSSA) - H1 blockade causes sedation and appetite increase; 5-HT2C blockade adds appetite stimulation; alpha-2 blockade enhances NA and 5-HT release; MORE sedating at 15mg than 30mg (paradox); ideal for elderly with insomnia + poor appetite + depression; rare risk of agranulocytosis.
ADRTs are legally binding under MCA 2005 - for life-sustaining treatment must be written, signed, witnessed, and include 'even if life at risk' statement; cannot demand treatment; cannot refuse basic care; cannot request euthanasia; check validity before proceeding; overriding a valid ADRT = assault.
Pain is the most common treatable cause of behavioural change in dementia; use validated pain tools (Abbey, PAINAD); PINCH ME mnemonic for underlying causes; trial analgesia before antipsychotics; NICE says address cause before pharmacotherapy; grimacing on repositioning = pain indicator.
Vascular dementia - NICE does not recommend ChEIs or memantine unless comorbid AD/PDD/DLB; focus on secondary prevention (antiplatelets, BP control, statins); many have mixed dementia where ChEIs are appropriate; not licensed for pure vascular dementia; address modifiable vascular risk factors.
Donepezil perioperatively - prolongs succinylcholine action (inhibits plasma cholinesterase); can cause bradycardia (vagal tone); inform anaesthetic team; avoid anticholinergic premedication; high delirium risk (~50%); capacity assessment for consent; continue donepezil perioperatively if possible; avoid/use succinylcholine with caution; prefer rocuronium.
St John's Wort - potent CYP3A4/CYP2C9 inducer and P-gp inducer; reduces levels of warfarin, OCP, ciclosporin, antiretrovirals, digoxin; serotonin syndrome risk with SSRIs; MHRA warnings; over-the-counter availability increases risk; always ask about herbal remedies; ginkgo = bleeding risk; kava = hepatotoxicity.
CAM - 4 features: acute onset + fluctuating, inattention, disorganised thinking, altered consciousness; requires 1+2 plus 3 or 4; sensitivity ~94%, specificity ~89%; inattention is the CORE feature; 4AT is a simpler alternative; NICE recommends validated screening in at-risk patients.
ECT per NICE TA59 - for severe/life-threatening/treatment-resistant depression, catatonia, prolonged mania; response rate 60-90% (80-90% for psychotic depression); particularly useful in elderly; bilateral > unilateral efficacy but more cognitive effects; 6-12 sessions; consent/Section 58 requirements.
Coercive control indicators - constant presence, speaking for the person, hostility when asked to leave; always see vulnerable adults alone when possible; professional curiosity is essential; Serious Crime Act 2015 criminalised coercive control; document factually; discuss with safeguarding lead; maintain inquiring mindset.
Korsakoff's syndrome - anterograde amnesia + confabulation + mammillary body atrophy; ~25% partial recovery with abstinence + thiamine; largely irreversible; Papez circuit damage; prevent by treating Wernicke's promptly with Pabrinex; long-term thiamine 100-300mg; most need supported accommodation.
Delirium → 2-8x increased dementia risk; accelerates existing cognitive decline; increases mortality; cognitive follow-up needed 3-6 months post-episode; delirium prevention = dementia prevention; HELP programme reduces incidence by 30-40%; both hyperactive and hypoactive subtypes carry long-term risk.
End-of-life dementia care - palliative principles: comfort, dignity, quality of life; review medications (stop non-essential); assess pain with behavioural scales; careful feeding decisions considering advance directives; support families; Gold Standards Framework; plan DNAR decisions early.
Capgras delusion - familiar person replaced by impostor; common in DLB (~15-25%); mechanism: disconnection between face recognition and emotional familiarity; management: approach by voice first, good lighting, avoid argument, ChEIs; Fregoli = different people are the same person in disguise.
Early SSRI activation risk - energy improves before mood, potentially enabling suicidal acts; monitor closely in first 2-4 weeks; elderly men have highest suicide completion rate; see within 1-2 weeks of starting; overall benefit of treatment far outweighs risk; untreated depression is the greater danger.
DLB triad - fluctuating cognition, visual hallucinations, parkinsonism; plus REM sleep behaviour disorder; DaTscan shows reduced dopamine uptake; cholinesterase inhibitors often very effective; ANTIPSYCHOTICS CONTRAINDICATED (severe neuroleptic sensitivity); 1-year rule distinguishes DLB from PDD.
TCAs contraindicated in urinary retention, angle-closure glaucoma, cardiac disease; strong anticholinergic effects; most dangerous in overdose (dosulepin); Beers/STOPP flag in elderly; SSRIs preferred; amitriptyline has ACB score 3; postural hypotension from α1 blockade; cardiac toxicity (QT prolongation).
Best interests decisions under MCA - consider past wishes, feelings, beliefs, values; consult family/friends; IMCA if no one to consult; decision-maker is treating clinician; Court of Protection for disputes; DoLS/LPS if deprivation of liberty; always explore least restrictive options.
Self-neglect - Care Act 2014 safeguarding category; balancing autonomy vs duty of care; capacity does not remove need for support; maintain relationship and offer help; explore underlying causes (depression, psychosis); multi-agency approach; proportionate intervention; document capacity and risk decisions.
ADRT - legally binding under MCA 2005 if valid and applicable; for life-sustaining treatment must be written, signed, and witnessed with specific statement; same legal force as contemporaneous refusal; family cannot override; invalidated by withdrawal, subsequent LPA, or inconsistent actions; healthcare professionals protected if unaware.
Depression in elderly - SSRIs first-line (start low, go slow); citalopram max 20mg (MHRA); elderly men have highest suicide rate; more somatic symptoms, less psychological complaints; monitor for hyponatraemia; avoid TCAs (anticholinergic burden); mirtazapine useful for appetite/sleep.
Late-onset psychosis + cognitive decline - always investigate for underlying dementia; cognitive assessment + MRI brain; FTD can present with personality change and bizarre beliefs; AD causes simpler delusions (theft, infidelity); longitudinal follow-up is essential; DaTscan if DLB suspected.
NICE NG97 routine dementia bloods: FBC, U&Es, LFTs, calcium, glucose, TFTs, B12, folate - designed to exclude reversible causes; HIV serology is NOT routine but consider if at risk; also consider medication review (anticholinergics are cognitive culprits) and depression screening.
Carer support in dementia - NICE recommends psychoeducation, skills training, support groups, respite, and regular health assessment; carers have 30-50% depression rates; START programme is evidence-based; assess carers as individuals; Attendance Allowance and Carer's Allowance may be available.
Mirtazapine - ideal for depressed elderly with weight loss and insomnia; H1 antagonism = sedation + appetite; 5-HT2C antagonism = appetite; paradoxically more sedating at 15mg than 30mg; NaSSA mechanism; fewer drug interactions than SSRIs; monitor for rare agranulocytosis; start 15mg nocte.
') reduces carer distress and conflict.
RBD - loss of REM atonia from brainstem degeneration; 80-90% develop synucleinopathy (DLB, PD, MSA) within 10-15 years; diagnose with polysomnography; treat with melatonin (first-line) or clonazepam; bedroom safety essential; SSRIs can worsen RBD.
1-year rule - PDD: parkinsonism >1 year before dementia; DLB: dementia within 1 year of or before parkinsonism; same Lewy body pathology (alpha-synuclein); ~80% of PD patients develop dementia; rivastigmine is licensed for PDD; both on the Lewy body disease spectrum.
PD psychosis - visual hallucinations + paranoia in ~20-40% of PD patients; due to Lewy body pathology + dopaminergic medication; management: exclude delirium → simplify dopaminergic drugs → quetiapine or clozapine; NEVER typical antipsychotics or risperidone/olanzapine; pimavanserin is a newer option.
Olanzapine has the highest metabolic risk - when significant weight gain or metabolic abnormalities develop, discuss switching to aripiprazole or another metabolically neutral antipsychotic using gradual cross-titration.
Thought insertion is defined by the experience of alien thoughts placed in the mind by an external agency - the patient recognises these as foreign, unlike in OCD where intrusive thoughts are recognised as one's own.
Substance-induced psychosis requires temporal association with substance use and physical signs of intoxication - approximately 20-50% of cannabis-induced psychoses may transition to schizophrenia, warranting follow-up after resolution.
The at-risk mental state (ARMS) is characterised by attenuated psychotic symptoms, functional decline, and often genetic risk - approximately 22% transition to psychosis within 3 years, and NICE recommends monitoring and CBT without routine antipsychotic use.
NMS presents with the tetrad of hyperthermia, lead-pipe rigidity, autonomic instability, and altered consciousness - stop the causative agent immediately, transfer to ITU, and treat with dantrolene and bromocriptine.
Antipsychotic use in pregnancy requires individual risk-benefit assessment - abrupt cessation risks relapse; pre-conception counselling, specialist perinatal input, and medications with the best safety data are recommended.
Acute dystonia requires immediate IM procyclidine 5mg - it most commonly occurs in young males within 72 hours of starting high-potency typical antipsychotics; always assess for laryngeal involvement as this can compromise the airway.
Smoking cessation can cause life-threatening clozapine toxicity by reducing CYP1A2 induction - reduce clozapine dose by 30-50% when patients stop smoking; NRT does NOT compensate because it is smoke, not nicotine, that induces CYP1A2.
Second-generation LAIs available in the UK include paliperidone palmitate (monthly/3-monthly), risperidone LAI (fortnightly), and aripiprazole LAI (monthly) - first-generation depots include flupentixol, zuclopenthixol, fluphenazine, and haloperidol decanoates.
Ciprofloxacin inhibits CYP1A2 and can cause dangerous clozapine toxicity - avoid this combination; if unavoidable, reduce clozapine dose and monitor levels urgently. Fluvoxamine is an even more potent CYP1A2 inhibitor.
Clozapine starts at 12.5mg once or twice daily with slow titration over 2-3 weeks - monitor vital signs daily during titration; myocarditis risk peaks at weeks 2-4; rapid dose escalation risks cardiovascular collapse.
Oculogyric crisis is sustained involuntary upward eye deviation - a form of acute dystonia treated with IM procyclidine; always ask about and examine for laryngeal dystonia which can compromise the airway.
Quetiapine's 'fast-off' D2 binding explains its very low EPS and prolactin risk - rapid dissociation allows transient therapeutic D2 blockade without sustained nigrostriatal or tuberoinfundibular blockade.
Dantrolene is the specific skeletal muscle relaxant for NMS - it inhibits calcium release from the sarcoplasmic reticulum; use alongside bromocriptine (dopamine agonist), aggressive cooling, and IV fluids in ITU.
Hyperprolactinaemia causes sexual dysfunction by suppressing GnRH → FSH/LH → testosterone/oestrogen (hypogonadism) - sexual dysfunction affects 30-80% on antipsychotics and is a major cause of non-adherence.
Risperidone is most affected by CYP2D6 polymorphism - poor metabolisers have higher levels and more side effects; clozapine depends on CYP1A2, quetiapine on CYP3A4; amisulpride and paliperidone are renally excreted and less affected by CYP variants.
Fluvoxamine is the most potent CYP1A2 inhibitor - it can increase clozapine levels 3-10 fold, causing life-threatening toxicity; use alternative SSRIs (sertraline, citalopram) for comorbid conditions in patients on clozapine.
Psychotic depression is defined by delusions and/or hallucinations occurring during a depressive episode - mood-congruent themes include guilt, nihilism, and punishment; treatment requires antidepressant plus antipsychotic or ECT.
ECT is indicated for life-threatening severe depression (unable to eat/drink, severe psychomotor retardation) - it has the fastest onset of any antidepressant treatment; NICE recommends it when rapid response is needed or other treatments have failed.
After failure of two SSRIs, NICE recommends switching class - mirtazapine, venlafaxine, or a TCA; use cross-tapering when switching; reserve MAOIs and augmentation strategies for later in the treatment algorithm.
SSRI-induced sexual dysfunction affects 30-70% and is a major adherence issue - switch to mirtazapine, bupropion, vortioxetine, or agomelatine for lower sexual dysfunction rates; discuss proactively as patients often do not volunteer this complaint.
ECT commonly causes temporary anterograde and retrograde amnesia that largely resolves within 1-3 months - bilateral ECT has more cognitive effects than unilateral; ultra-brief pulse reduces cognitive impact; monitor cognition throughout treatment.
Lithium monitoring requires lithium levels, renal function, and TFTs every 6 months - lithium causes nephrotoxicity and hypothyroidism; check calcium annually (hyperparathyroidism risk); target level 0.6-0.8 mmol/L for depression.
SSRI activation syndrome (anxiety, agitation, nausea in week 1) is due to initial 5-HT1A autoreceptor stimulation - self-limiting within 1-2 weeks; manage with reassurance, short-term benzodiazepine, and continued SSRI; warn all patients at initiation.
Dysthymia = chronic low-grade depression lasting ≥2 years without meeting full episode criteria - often has early onset; 'double depression' = major episode superimposed on dysthymia; treatment follows same principles as major depression.
Lamotrigine prevents bipolar depressive episodes but NOT manic episodes - requires slow titration over 6-8 weeks due to SJS risk; halve the dose with valproate co-prescription; not effective for acute mania.
Valproate must NOT be used in women of childbearing potential without a Pregnancy Prevention Programme - 10% major malformation rate, 30-40% neurodevelopmental effects; the MHRA Annual Risk Acknowledgement Form must be signed.
Olanzapine provides rapid sedation (H1 blockade) alongside antimanic efficacy - useful for acutely agitated, sleepless manic patients; but carries metabolic risks for long-term use; adjunctive benzodiazepines can supplement less-sedating alternatives.
Lithium-induced hypothyroidism affects ~20% of long-term users - manage with levothyroxine replacement, do NOT stop lithium; monitor TFTs every 6 months; untreated hypothyroidism can worsen depression and cause rapid cycling.
Mixed episodes combine manic and depressive symptoms simultaneously - they carry the HIGHEST suicide risk of all mood episodes; treat as mania (antipsychotics/valproate); AVOID antidepressants; lithium may be less effective than in pure mania.
Valproate causes dose-dependent thrombocytopenia (5-18%) and hepatotoxicity (transaminase elevation common, fatal hepatic failure rare) - monitor FBC and LFTs regularly; stop if transaminases >3x normal or platelets <75; weight gain, hair loss, and PCOS are other important side effects.
Psychotic mania is defined by the presence of delusions and/or hallucinations - occurs in ~50-60% of manic episodes; grandiose delusions are most common; treatment requires an antipsychotic component; mood-congruent psychotic features are typical.
Lithium's mechanism primarily involves inositol depletion (IMPase inhibition) and GSK-3 inhibition - these lead to neuroprotection, BDNF upregulation, and dampening of overactive intracellular signalling; the multiple mechanisms explain its broad therapeutic profile.
Stable lithium monitoring: levels every 3 months (first year), then every 6 months; renal and thyroid function every 6 months; calcium annually - increase monitoring frequency during illness, medication changes, or declining renal function.
Lamotrigine carries SJS/TEN risk (~1 in 1,000 adults) - slow titration over 6+ weeks is mandatory to minimise risk; halve the dose with valproate; any rash during titration = stop and seek urgent medical review; NEVER rechallenge after SJS/TEN.
After acute mania resolves, gradually withdraw the antipsychotic over weeks while maintaining the mood stabiliser - continue the antipsychotic long-term only if it is part of the prophylactic strategy or if the patient relapses upon withdrawal.
Thiazide diuretics increase lithium levels by 20-40% through compensatory proximal tubular sodium/lithium reabsorption - part of the 'NAD' interaction; use calcium channel blockers or beta-blockers for hypertension in lithium patients instead.
Lorazepam is the preferred adjunctive benzodiazepine for acute mania agitation and insomnia - use short-term (days to 2 weeks) while the antimanic agent takes effect; monitor for excess sedation when combined with sedating antipsychotics.
GAD requires ≥6 months of excessive worry about multiple life areas with associated somatic symptoms - 60% comorbidity with depression; NICE recommends stepped care starting with guided self-help before pharmacotherapy.
NICE first-line drug for GAD is sertraline (SSRI) - warn about initial worsening of anxiety; continue for ≥12 months after remission; pregabalin is second-line; benzodiazepines only short-term (2-4 weeks maximum).
Clark's model (1986) - panic is maintained by catastrophic misinterpretation of bodily sensations creating a vicious cycle; CBT targets this with interoceptive exposure and dropping safety behaviours; the model underpins NICE-recommended CBT for panic.
Specific phobia first-line treatment is CBT with graded exposure - can be highly effective even in a single extended session; blood-injection-injury phobia is unique (vasovagal response - use applied tension, not relaxation); medication plays minimal role.
OCD requires higher SSRI doses than depression - fluoxetine up to 60mg for OCD vs 20mg for depression; adequate trial is ≥12 weeks at maximum tolerated dose; only serotonergic drugs are effective in OCD.
SSRIs initially worsen anxiety due to 5-HT2C stimulation before 5-HT1A autoreceptor desensitisation - start at low dose in anxiety disorders; therapeutic effect takes 4-6 weeks; consider short-term benzodiazepine cover for initial worsening.
Clark and Wells' social anxiety model - self-focused attention creates a distorted internal 'image' used to judge social performance; treatment targets self-focused attention, safety behaviours, and pre/post-event rumination; model-specific CBT is highly effective.
Ego-dystonic intrusive harm thoughts in perinatal OCD do NOT indicate increased risk - the distress, resistance, and safety behaviours distinguish them from psychotic phenomena; treat with CBT/ERP and SSRIs; differentiate from puerperal psychosis where risk IS present.
Partial SSRI response in PTSD - increase to maximum dose first before switching; NICE recommends sertraline, paroxetine, or venlafaxine; continue for ≥12 months; benzodiazepines can worsen PTSD outcomes; psychological treatment is preferred over medication.
Lorazepam - shortest half-life (10-20 hours), no active metabolites, used for rapid tranquillisation; diazepam - longest acting, preferred for withdrawal tapering; benzodiazepines increase FREQUENCY of GABA chloride channel opening (vs barbiturates increase DURATION).
Clomipramine - greater cardiac toxicity in overdose than SSRIs (QRS prolongation, arrhythmias), lowers seizure threshold; ECG before starting; most serotonergic TCA; maximum 250mg daily; avoid in overdose-risk patients; valuable for SSRI-refractory OCD and panic.
Reassurance in health anxiety is a safety behaviour - provides brief relief but maintains anxiety through negative reinforcement; Warwick and Salkovskis model identifies misinterpretation + safety behaviours + selective attention + emotional reasoning; CBT targets all four maintaining factors.
ERP hierarchy - grade from lowest to highest SUDS; direct contact + response prevention generates maximum anxiety; progress when SUDS reduces by 50%; therapist models first; 10-15 items; overlearning and variability enhance generalisation.
Salkovskis' OCD model - inflated personal responsibility transforms normal intrusions into obsessions; CBT targets responsibility appraisals through behavioural experiments and responsibility pie charts; thought-action fusion (TAF) is a related but distinct concept feeding into responsibility beliefs.
Dugas' model - intolerance of uncertainty is central to GAD; four components: IU, positive worry beliefs, negative problem orientation, cognitive avoidance; treatment involves deliberately introducing uncertainty through behavioural experiments; IU is transdiagnostic but most central in GAD.
Depersonalisation (detachment from self) and derealisation (environment feels unreal) are dissociative symptoms common in panic attacks - NOT psychotic; patients catastrophically misinterpret these as 'going mad'; psychoeducation is therapeutically powerful; chronic forms constitute a separate dissociative disorder.
NICE recommends structured therapy ≥3 months for BPD - DBT (skills: mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness) or MBT (mentalisation); AVOID medication for BPD itself; AVOID short-term admission for BPD crises.
ASPD diagnosis requires conduct disorder before age 15 - cannot be diagnosed before age 18; prevalence ~3% males; 50-80% of male prisoners; callous-unemotional traits in childhood are the strongest predictor of adult ASPD; limited evidence for treatment.
Bodily distress disorder management - validate symptoms as real, regular scheduled appointments, single coordinating clinician, limit investigations, graded reactivation, biopsychosocial framework; do NOT dismiss or over-investigate; antidepressants may help.
Purging by vomiting → hypokalaemia (most dangerous - cardiac arrhythmias) + metabolic alkalosis; ECG: flat T waves, U waves, prolonged QT; also causes dental erosion, parotid enlargement, Russell's sign, oesophageal tears; laxative abuse → metabolic acidosis (different pattern).
OCPD vs OCD - OCPD is ego-syntonic (traits seen as strengths) while OCD is ego-dystonic (intrusions are unwanted); OCPD involves perfectionism and rigidity as personality traits, not obsessions/compulsions; most prevalent PD (~2-8%); can co-occur with OCD; treatment challenges due to limited insight.
Dissociative stupor - decreased movement/speech triggered by emotional distress with normal investigations; distinguish from catatonia (needs ≥3 specific motor features), depressive stupor, and organic causes; management: safety + psychotherapy + grounding techniques; classified under dissociative disorders in ICD-11.
Fluoxetine requires longer washout periods than other SSRIs due to its 4-6 day half-life and active metabolite (4-16 day half-life) - at least 1-2 weeks for switching to another serotonergic drug, at least 5 weeks before starting an MAOI.
BPD vs bipolar mood - BPD: rapid (minutes-hours), reactive, interpersonal triggers, anger/emptiness predominate; bipolar: sustained (days-weeks), autonomous, elation/depression predominate; can co-occur (~10-20%); longitudinal history essential for diagnosis.
ICD-11 schizophrenia requires characteristic symptoms for at least one month, has removed classical subtypes, and uses symptom qualifiers instead - third-person auditory hallucinations remain a core diagnostic feature.
Negative symptoms are the strongest predictor of functional outcome in schizophrenia and respond poorly to antipsychotics - always differentiate primary from secondary negative symptoms (medication effects, depression, understimulation).
Thought echo (Gedankenlautwerden) is the perception of one's own thoughts spoken aloud - it is a Schneiderian first-rank symptom distinct from thought broadcasting (which implies others can access the thoughts).
CPMS Red alert (neutrophils <1.5) requires immediate permanent cessation of clozapine - the highest risk period for agranulocytosis is the first 18 weeks, hence weekly monitoring during this period.
Made acts involve loss of agency over motor actions attributed to external control - distinguish from somatic passivity (imposed sensations), made impulses (imposed urges), and made feelings (imposed emotions).
Progressive cognitive decline in stable schizophrenia is NOT expected and requires investigation for comorbid neurodegenerative disease - diagnostic overshadowing must be avoided to prevent delayed diagnosis of treatable conditions.
Aripiprazole is a dopamine D2 partial agonist that stabilises dopamine activity - antagonist in hyperdopaminergic areas (reducing positive symptoms), agonist in hypodopaminergic areas (potentially improving negative symptoms) - hence its description as a 'dopamine system stabiliser.'
Cotard delusion (nihilistic delusion) involves beliefs of being dead, non-existent, or having rotting organs - most commonly seen in psychotic depression but also occurs in schizophrenia and organic conditions.
Thought blocking is the sudden cessation of thought mid-speech - it becomes the first-rank symptom of thought withdrawal only when the patient attributes it to an external agency removing their thoughts.
All antipsychotics work through D2 receptor antagonism (or partial agonism) - therapeutic efficacy requires 60-80% occupancy, and EPS risk increases above 80% occupancy.
Olanzapine carries the highest metabolic risk among common antipsychotics - in a person with LD developing diabetes and obesity, switching to a metabolically neutral alternative (e.g. aripiprazole) should be prioritised alongside lifestyle interventions and metabolic management.
When auditory hallucinations have mood-congruent depressive content (worthlessness, guilt, self-harm commands), psychotic depression is more likely than schizophrenia - this distinction determines treatment approach and is commonly missed in people with LD.
Challenging behaviour always serves a function - escape, attention, tangible, or sensory - and functional behavioural assessment using ABC analysis is essential for designing effective, individualised interventions.
PBS combines behavioural science with person-centred values - it focuses on improving quality of life, teaching skills, and meeting unmet needs rather than simply suppressing challenging behaviour through punishment or medication.
The MCA functional test assesses four abilities - understand, retain, use/weigh, and communicate - failure in any one constitutes incapacity, and all practicable steps to support decision-making must be taken before concluding incapacity.
Carbamazepine and other sodium channel blockers should be avoided in Lennox-Gastaut syndrome as they can worsen generalised seizure types - valproate, rufinamide, and clobazam are preferred options for this severe epileptic encephalopathy.
Capacity for surgical consent requires understanding the nature, purpose, risks, benefits, and alternatives relevant to the specific decision - information must be presented accessibly, and multiple assessment sessions may be needed.
Setting events are background conditions that alter vulnerability to triggers - poor sleep, pain, illness, and staffing changes do not directly cause challenging behaviour but lower the threshold at which antecedents trigger it.
STOMP-aligned medication reviews systematically evaluate indication, current need, side effects, and reduction potential - automatic dose increases without clinical justification are antithetical to the campaign's principles.
IMCA instruction is mandatory for unbefriended adults lacking capacity when serious medical treatment or accommodation changes are being decided - it is a statutory safeguard under the MCA, not discretionary.
Vagus nerve stimulation reduces seizure frequency by ~50% in about one-third of patients with drug-resistant epilepsy - it is particularly useful in LD as it requires no medication adherence and has minimal cognitive side effects.
Everolimus (mTOR inhibitor) specifically targets the dysregulated pathway in TSC - it reduces seizure frequency in drug-resistant TSC epilepsy and also treats SEGAs and renal angiomyolipomas, providing mechanism-based therapy.
Tardive dyskinesia presents with involuntary orofacial movements after prolonged antipsychotic use - people with LD are at increased risk, regular AIMS screening is essential, and management includes dose reduction, switch to clozapine, or VMAT2 inhibitors.
SPELL (Structure, Positive approaches, Empathy, Low arousal, Links) is the NAS framework for autism support - it provides a holistic, person-centred approach applicable across all settings and severity levels.
Pica management requires a comprehensive MDT approach - always check for nutritional deficiencies (iron, zinc), conduct functional analysis, modify the environment while maintaining quality of life, and monitor for medical complications.
The NACHBID study showed antipsychotics were no better than placebo for challenging behaviour in LD - prescribing should be reserved for diagnosed psychiatric conditions, with PBS as the primary approach for challenging behaviour.
Fragile X syndrome is the commonest inherited cause of LD - look for the triad of long face, large ears, and macroorchidism, plus trinucleotide repeat expansion with anticipation through maternal transmission.
Depression diagnosis in moderate-severe LD relies on informant reports of behavioural change from baseline, biological symptoms, and adapted criteria (DC-LD) - standard self-report measures are unreliable when verbal communication is limited.
Psychosis in moderate-severe LD presents predominantly through behavioural change and functional decline - Sovner's four factors (intellectual distortion, psychosocial masking, cognitive disintegration, baseline exaggeration) explain why standard symptom descriptions are often inapplicable.
Prader-Willi (paternal deletion) and Angelman (maternal deletion) syndromes at 15q11-13 are the paradigm examples of genomic imprinting - same region, different parent of origin, completely different phenotypes.
Smith-Magenis syndrome (17p11.2 deletion, RAI1 gene) has the unique combination of inverted melatonin circadian rhythm causing severe sleep disturbance, pathognomonic self-hugging behaviour, and onychotillomania - melatonin plus morning beta-blocker may help the sleep disorder.
Focal seizures with impaired awareness (complex partial) present with automatisms, impaired consciousness lasting 30-60 seconds, and post-ictal confusion - epilepsy affects 20-30% of people with LD, increasing with disability severity.
Perinatal causes of LD (birth asphyxia, prematurity, birth trauma) account for approximately 10-15% of identified cases - therapeutic hypothermia for HIE within 6 hours is an important preventive intervention.
For tangibly reinforced behaviour, teach a functionally equivalent communicative response (FCT) and provide scheduled access to reduce motivation - the replacement behaviour must be more efficient than the challenging behaviour.
For attention-maintained behaviour, provide frequent non-contingent positive attention to reduce the establishing operation - combine with FCT to teach appropriate attention-seeking and plan neutral, minimal responses to challenging behaviour.
Behavioural phenotypes are characteristic patterns of behaviour consistently associated with specific genetic conditions - recognising them aids diagnosis, guides management, and predicts likely psychiatric comorbidities.
Diagnostic overshadowing by GPs is a significant cause of health inequality - biological symptoms of depression (weight loss, appetite change, sleep disturbance, tearfulness) should prompt assessment and treatment regardless of intellectual level.
Restrictive practices must be last resort, least restrictive, and shortest duration - multiple daily restraints indicate PBS plan failure requiring urgent review, and prone restraint carries risk of positional asphyxia.
Learning disability requires the triad of impaired intellectual functioning, impaired adaptive functioning, and developmental onset (before age 18) - all three must be present, and adaptive functioning spans conceptual, social, and practical domains.
Active support provides graded assistance to maximise engagement in meaningful activities - it reduces challenging behaviour by addressing the disengagement and lack of stimulation that often drive behaviours in residential LD settings.
Diagnostic overshadowing is the tendency to attribute symptoms of mental illness to the learning disability itself - it is the single most important barrier to psychiatric diagnosis and treatment in people with LD.
Adults with Down syndrome have near-universal Alzheimer neuropathology by age 40 due to APP gene triplication - baseline functional assessments should be established by age 30 to detect subsequent decline.
TSC is autosomal dominant with variable expressivity, caused by TSC1 or TSC2 mutations dysregulating the mTOR pathway - learning disability occurs in 50%, epilepsy in 80-90%, and TAND encompasses the range of neuropsychiatric complications.
Challenging behaviour describes impact on safety and access, not a diagnosis - it can coexist with, result from, or be independent of mental illness, and distinguishing these relationships is essential for appropriate intervention.
Autistic special interests are ego-syntonic and pleasurable, without intrusive thoughts or anxiety-driven rituals - they should be channelled and accommodated rather than suppressed, unlike OCD which requires treatment with ERP and/or SSRIs.
Adapted CBT is the best-evidenced psychological therapy for anxiety and depression in mild-moderate LD - key adaptations include simplified language, visual materials, shorter sessions, behavioural emphasis, and carer involvement as co-therapists.
Multi-function challenging behaviour requires a comprehensive PBS plan with distinct strategies for each function - staff must be trained to identify contextual cues indicating which function is operating to apply the correct intervention in real-time.
Lithium's narrow therapeutic index and reliance on patient-reported toxicity symptoms make it particularly challenging in LD - more frequent monitoring, carer education about toxicity signs, and reasonable adjustments for blood tests are essential.
Naltrexone targets the endogenous opioid hypothesis of self-injurious behaviour - it is most effective for stereotypic, repetitive SIB and should be combined with behavioural interventions within a PBS framework.
Scatter plots reveal temporal patterns in challenging behaviour - they show when behaviour is most likely to occur across time and days, guiding more focused functional assessment of the environmental factors operating during those periods.
ASD prevalence increases with LD severity - approximately 20-30% overall but up to 40-50% in severe-profound LD - diagnosis requires distinguishing autistic features from developmental delay using adapted assessment tools like DISCO.
Down syndrome (Trisomy 21) is the commonest chromosomal cause of LD - AVSD is the characteristic cardiac defect, and early-onset Alzheimer's disease is a major concern due to APP gene triplication on chromosome 21.
Severe LD (IQ 20-34) typically presents with very limited verbal communication, dependence in self-care, and need for continuous supervision - Makaton and other AAC methods are essential communication supports.
Mild LD (IQ 50-69) typically allows mainstream schooling with support, basic literacy, independent self-care, and employment in unskilled roles - difficulties with abstract concepts like money management and planning are characteristic.
Profound LD (IQ <20) involves minimal communication, severe motor impairment, total dependence in care, and usually has an identifiable organic aetiology - comorbid epilepsy and sensory impairments are very common.
The Pritchard criteria assess cognitive capacity to participate in trial proceedings - they do not require demonstration of remorse, moral understanding, or emotional response to the alleged offence.
22q11.2 deletion syndrome (DiGeorge/velocardiofacial) is remembered by the mnemonic CATCH-22: Cardiac, Abnormal facies, Thymic hypoplasia, Cleft palate, Hypocalcaemia - it confers a 25-30% lifetime risk of schizophrenia.
The Vineland-3 assesses three core adaptive behaviour domains - Communication, Daily Living Skills, and Socialisation - it is administered through caregiver interview and is essential alongside IQ testing for learning disability diagnosis.
Frequent GTCS, especially nocturnal ones, are the strongest modifiable risk factor for SUDEP - people with LD are at increased risk due to uncontrolled epilepsy, and nocturnal seizure monitoring devices are important risk-reduction tools.
Sensory hyper-reactivity in autism involves heightened sensitivity causing avoidance and distress - occupational therapy assessment guides environmental modifications and sensory strategies that form a crucial part of PBS planning.
Psychotropic polypharmacy for 'challenging behaviour' without clear psychiatric diagnoses represents the archetypal STOMP concern - systematic review, establishing diagnostic indications, and planned sequential reduction are essential.
When challenging behaviour has a sensory function, address the sensory need directly - replace aversive stimuli (uncomfortable clothing), provide preferred alternatives, and conduct comprehensive OT sensory assessment to guide environmental and personal modifications.
Depression in mild LD should be treated with SSRIs following standard NICE guidelines with reasonable adjustments - start low, go slow, monitor side effects actively through carers, and use simplified regimens to support adherence.
The Valproate PPP mandates annual Risk Acknowledgement Form completion, effective contraception, and specialist review - it applies to all women of childbearing potential including those with LD, requiring reasonable adjustments and capacity assessment.
Rett syndrome is caused by MECP2 mutations on the X chromosome - the hallmark is loss of purposeful hand movements replaced by stereotypic wringing after a period of apparently normal early development, almost exclusively in females.
Inappropriate sexual behaviour in LD often reflects inadequate sex and relationships education rather than paraphilia - comprehensive assessment of knowledge gaps and adapted educational programmes should precede any forensic or pharmacological intervention.
Partial response to SSRIs at 6 weeks warrants dose optimisation rather than switching - start low, go slow, but ensure adequate therapeutic doses are reached with 8-12 week trials before concluding treatment failure.
The MCA decision-maker is the person or body responsible for the specific act - for accommodation, typically the local authority, who must consult relevant parties but makes the final decision following the statutory best interests checklist.
Low-dose quetiapine for insomnia in LD is inappropriate off-label prescribing targeted by STOMP - insomnia should be assessed comprehensively and managed with sleep hygiene, environmental modifications, and melatonin if pharmacotherapy is needed.
Melatonin for sleep-onset insomnia in LD/autism - start low (0.5-1mg), give 30-60 minutes before bedtime, titrate gradually, and always combine with behavioural sleep strategies for best outcomes.
The right to make an unwise decision is a fundamental MCA principle - a capacitous person with LD can refuse blood tests, but clinicians should ensure the decision is fully informed and explore all reasonable adjustments before accepting the refusal.
Transforming Care aimed to move people with LD/autism from inappropriate inpatient settings to community support - prompted by Winterbourne View, it used Care and Treatment Reviews and community investment, though targets were not fully achieved.
Epilepsy prevalence increases with LD severity - approximately 30-50% in severe-profound LD compared to 0.5-1% in the general population - shared brain pathology explains this relationship, and epilepsy in LD is typically more severe and treatment-resistant.
Levetiracetam commonly causes irritability and aggression, particularly in people with LD - always consider medication side effects when behavioural deterioration has a clear temporal relationship with drug initiation or dose change.
Learning disability involves global intellectual impairment (IQ <70) while specific learning difficulties (dyslexia, dyscalculia) affect particular academic domains with preserved overall intelligence - this distinction determines service eligibility and legal protections in the UK.
Moderate learning disability (ICD-10 F71, IQ 35-49) - needs prompting for self-care, limited literacy, simple supervised work; diagnosis requires impaired intellectual AND adaptive functioning, not IQ alone.
Klinefelter syndrome (47,XXY) presents with tall stature, small testes, gynaecomastia, and borderline-to-mild intellectual impairment - psychiatric comorbidities (depression, anxiety, ASD) are common, and testosterone replacement addresses hypogonadism.
Behaviour occurring predominantly when alone suggests automatic/sensory reinforcement - treatment involves environmental enrichment, matched stimulation providing similar sensory input safely, and increased engagement rather than social contingency manipulation.
The NHS Annual Health Check for LD covers physical health, sensory assessment, medication review, immunisations, epilepsy, and mental health - it was introduced to address health inequalities highlighted by CIPOLD and LeDeR, not to re-assess intellectual functioning.
People with LD have 3-4 times the rate of mental health problems - biopsychosocial vulnerability explains this, and the full range of psychiatric disorders can occur at all severity levels of LD.
Williams syndrome (7q11.23 deletion) produces the characteristic combination of elfin facies, supravalvular aortic stenosis, cocktail party personality, and preserved language with impaired visuospatial skills - the elastin gene deletion causes the cardiovascular features.
Transference interpretations are the most therapeutically potent because they address unconscious relational patterns as they are actively enacted in the here-and-now of the therapeutic relationship - Malan's triangles provide the linking framework between current, transferential, and historical patterns.
CBT sessions follow a structured format - mood check, agenda setting, homework review, main work, new homework, and feedback - homework completion between sessions is one of the strongest predictors of therapeutic outcome.
Graded exposure systematically progresses through an anxiety hierarchy - habituation and inhibitory learning occur at each level, and exposure must be of sufficient duration (45-60 minutes), frequent, and progressed at the patient's pace.
Bion's containment involves the therapist receiving, processing, and returning the patient's unbearable emotions in a more manageable form - this develops the patient's own alpha function (capacity for emotional processing) that was inadequately developed in early relationships.
Kohut's self psychology understands narcissism as resulting from selfobject failures (inadequate mirroring, idealisation, twinship) - treatment involves empathic immersion and understanding narcissistic needs as developmental deficits rather than simply confronting grandiosity.
Freud's anal stage (18 months-3 years) is associated with the 'anal triad' of orderliness, parsimony, and obstinacy - while no longer accepted literally, the concepts of control, ambivalence, and perfectionism remain relevant to psychodynamic understanding of obsessional personality.
DBT's biosocial theory proposes that BPD arises from biological emotional vulnerability interacting with an invalidating environment - treatment dialectically balances acceptance and change across four components: individual therapy, skills group, phone coaching, and consultation team.
Reciprocal roles are CAT's concept of internalised relational templates from early experiences - they consist of paired roles enacted in current relationships, mapped on the Sequential Diagrammatic Reformulation, and targeted through recognition and revision.
IPT identifies four interpersonal problem areas - grief, role disputes, role transitions, and interpersonal deficits - marital breakdown represents a role transition requiring mourning of the old role and development of mastery in the new one.
Radical acceptance acknowledges unchangeable reality without approval - it reduces suffering by stopping the struggle against what cannot be changed, while the dialectical balance ensures continued effort to change what can be changed.
The CAT goodbye letter marks the ending, consolidates learning, and provides a lasting reference - endings are given particular therapeutic attention because many patients have experienced difficult separations, and a well-managed ending provides a corrective emotional experience.
IPT for grief facilitates the mourning process - the therapist encourages emotional expression about the deceased, reviews the relationship comprehensively, and helps the patient rebuild social connections and develop new interests.
MBCT has the strongest evidence for preventing depressive relapse in patients with three or more previous episodes - it reduces relapse by approximately 40-50% by teaching mindful awareness and decentring from ruminative thought patterns.
IPT's interpersonal deficits problem area addresses pervasive social isolation and difficulty forming relationships - the therapeutic relationship itself becomes a model for connection, and the focus is on reviewing past relationship patterns and building new social connections.
Psychotherapy outcomes follow a negatively accelerating curve - most improvement occurs early, with diminishing returns, and approximately 50% improve by session 8-13; routine outcome monitoring helps identify patients who need treatment adjustment.
Klein's depressive position is a developmental achievement, not a disorder - it involves recognising others as whole persons with good and bad qualities, enabling ambivalence, guilt, and reparation, and represents psychological maturation beyond the earlier splitting of the paranoid-schizoid position.
Teleological mode recognises mental states only through observable actions - 'you only care if you DO something' - the MBT therapist validates the underlying need while maintaining boundaries and gently exploring the assumption that caring must be demonstrated through concrete action.
The CAT reformulation letter narrates the patient's story, links past experiences to current relational patterns, and creates a shared understanding - it is written collaboratively around session 4-5 and accompanies the visual SDR diagram.
Beck's cognitive triad - negative views of self, world, and future - is the foundational model of CBT for depression, with negative automatic thoughts arising from deeper core beliefs formed through early experiences.
Countertransference is the therapist's emotional response to the patient - modern psychodynamic theory views it as valuable clinical data about the patient's relational patterns, requiring regular supervision to understand and manage therapeutically.
Splitting involves inability to integrate good and bad aspects of self and others - it is a hallmark primitive defence in BPD, and therapeutic work involves developing the capacity for ambivalence and integration of contradictory feelings.
Projection attributes one's own unacceptable feelings to others - it is a primitive defence common in paranoid states, and therapeutic work involves gentle exploration of whether the attributed feelings might reflect the patient's own disowned emotions.
Vaillant's hierarchy classifies defences from psychotic (most primitive) through immature and neurotic to mature (most adaptive) - mature defences (humour, sublimation, altruism, suppression, anticipation) are associated with psychological health and resilience.
Activity scheduling breaks the depression-inactivity cycle by gradually reintroducing mastery and pleasure activities - it is the core technique of behavioural activation, which has been shown to be as effective as full CBT for depression.
Reaction formation transforms an unacceptable impulse into its opposite - the excessive, rigid, guilt-driven quality of the behaviour (compulsive caregiving at the expense of self) distinguishes it from genuine, freely chosen altruism.
Displacement redirects emotion from a threatening target to a safer one - the feeling is preserved but misdirected, and therapeutic work involves helping the patient express emotions towards their original, anxiety-provoking target.
Emotional reasoning treats feelings as evidence for beliefs - 'I feel terrible therefore things are terrible' - challenging this distortion involves distinguishing between emotional experience and objective reality, recognising that emotions are valid but not reliable evidence.
Sleep restriction in CBT-I reduces time in bed to match actual sleep time - this consolidates sleep, increases sleep efficiency, and strengthens the bed-sleep association, with gradual extension as efficiency improves above 85-90%.
Bateman and Fonagy's MBT trial provided landmark RCT evidence for psychodynamically-informed treatment of BPD - MBT develops mentalisation capacity and demonstrated sustained improvements in self-harm, suicide attempts, and psychiatric symptoms at 8-year follow-up.
Freud's structural model (id, ego, superego) describes intrapsychic conflict between primitive drives (id), reality-oriented mediation (ego), and internalised morality (superego) - symptoms arise from failures of the ego to manage these competing demands.
Triangulation involves a child being drawn into parental conflict - structural family therapy (Minuchin) addresses this by strengthening the parental subsystem, establishing consistent boundaries, and disrupting cross-generational coalitions.
The four mentalising dimensions - automatic/controlled, self/other, cognitive/affective, internal/external - provide a framework for understanding mentalising imbalances in BPD and targeting interventions to restore balance across dimensions.
Circular questioning explores relational patterns by asking family members to comment on others' relationships - it is a core Milan systemic technique that reveals perspectives, highlights differences, and makes relational patterns visible without assigning blame.
The dialectical philosophy synthesises acceptance and change - the therapist simultaneously validates the patient's experience (acceptance) while working to change harmful patterns (change), moving fluidly between these complementary stances.
Psychic equivalence treats internal experience as identical to external reality - 'I feel it so it must be true' - the MBT therapist introduces uncertainty and alternative perspectives to restore the capacity for reflective mentalising.
MBT's curious, not-knowing stance models mentalising by approaching mental states with genuine curiosity - it avoids authoritative interpretations that risk exceeding the patient's mentalising capacity and instead uses empathic validation, clarification, and collaborative exploration.
Foulkes' four levels of group communication - current, transference, projective, and primordial - operate simultaneously in group analysis, with the group matrix as the shared communicative network and the therapist as conductor facilitating rather than directing.
Therapeutic neutrality is equidistance between intrapsychic forces (id/ego/superego) - it facilitates exploration of conflict without the therapist imposing their values, and must be distinguished from coldness or indifference.
Mentalisation is the capacity to understand behaviour through mental states - MBT targets this capacity in BPD, where it breaks down under emotional arousal, leading to pre-mentalistic modes (psychic equivalence, pretend mode, teleological mode).
Storming involves conflict, challenges to authority, and interpersonal friction - it is a necessary developmental stage that enables deeper cohesion if navigated successfully, and the therapist must contain anxiety while modelling constructive conflict management.
Salkovskis' OCD model identifies inflated responsibility as the key maintaining cognition - intrusive thoughts are universal but are misinterpreted in OCD as conferring personal responsibility for harm prevention, driving compulsive rituals.
Projective identification is a two-person process where projected material is actually induced in and enacted by the recipient - the therapist's task is to contain rather than enact it, and it is detected primarily through countertransference awareness.
All-or-nothing thinking is challenged using the continuum technique - placing experiences on a spectrum between extremes helps patients develop cognitive flexibility and recognise that 'good enough' outcomes are valuable, not failures.
Self-focused attention in social anxiety creates a distorted negative self-image that the patient mistakes for how they actually appear - treatment involves shifting attention externally, dropping safety behaviours, and using video feedback to correct the distorted self-perception.
The miracle question shifts from problem-focused to solution-focused thinking - it helps families envision a preferred future, identify concrete goals, and recognise existing resources, based on the SFBT principle that solutions are constructed, not derived from problem analysis.
CAT's three procedures - traps (vicious circles), dilemmas (false either/or choices), and snags (self-sabotage near goals) - describe how problematic patterns maintain difficulties and are mapped on the SDR for therapeutic recognition and revision.
Enmeshment involves diffuse boundaries with excessive closeness - when combined with a cross-generational coalition (parent-child alliance excluding the other parent), it places inappropriate burdens on children and undermines the parental subsystem.
The identified patient may carry or express difficulties belonging to the whole family system - systemic therapy assesses the relational context and functional role of symptoms rather than treating the presenting member in isolation.
DBT's target hierarchy always addresses life-threatening behaviours first, then therapy-interfering behaviours, then quality-of-life issues, then skills generalisation - the diary card tracks these targets and structures each session.
Narrative therapy's externalisation separates the problem from the person - 'the person is not the problem; the problem is the problem' - reducing shame and blame while enabling the person and family to develop a new relationship with the difficulty.
Fairburn's transdiagnostic model identifies over-evaluation of eating, shape, weight and their control as the core maintaining mechanism across eating disorders - CBT-E targets this alongside perfectionism, low self-esteem, interpersonal difficulties, and mood intolerance.
Dreams provide access to unconscious material in psychodynamic therapy - the therapist explores the patient's associations to dream content rather than imposing interpretations, and Freud's dream-work mechanisms (condensation, displacement, symbolisation) transform latent unconscious content into manifest dream imagery.
Passive aggression expresses hostility indirectly through procrastination, inefficiency, and subtle sabotage - it is an immature defence rooted in fear of direct confrontation, often manifesting in the therapeutic relationship through missed sessions and undermined homework.
Family-based treatment (Maudsley approach) has the strongest evidence for adolescent anorexia nervosa - it empowers parents to manage refeeding, progresses through three phases, and is NICE-recommended as first-line for young people with AN.
Safety behaviours are the key maintenance factor in health anxiety - checking and reassurance seeking prevent disconfirmation of threat beliefs and paradoxically maintain the disorder by reinforcing the idea that vigilance is necessary.
DIT is a brief (16-session) manualised psychodynamic therapy developed for IAPT services - it identifies a core unconscious relational pattern (IPAF) maintaining depression and was developed by Lemma, Target, and Fonagy to bring psychodynamic therapy into stepped-care.
Behavioural experiments test specific predictions through planned real-world experiences - they provide experiential evidence that is often more compelling than verbal cognitive restructuring alone, and are central to CBT for anxiety disorders.
Core beliefs are the deepest level of Beck's cognitive hierarchy - they are absolute, unconditional, and formed in childhood, influencing the generation of intermediate beliefs and automatic thoughts across all life domains.
TIPP skills (Temperature, Intense exercise, Paced breathing, Progressive relaxation) target physiological arousal in acute emotional crises - the temperature technique using the dive reflex provides the most rapid de-escalation.
Tuckman's stages - forming (polite, dependent), storming (conflict, challenge), norming (cohesion, shared expectations), performing (productive work), and adjourning (endings) - describe normal group development, with Bion's basic assumptions operating alongside.
Comprehensive DBT requires four modes - individual therapy, skills group, telephone coaching, and therapist consultation team - the consultation team is a unique and essential component that supports therapist wellbeing and treatment adherence.
The therapeutic alliance is the strongest consistent predictor of psychotherapy outcome across modalities - while the 'Dodo bird verdict' suggests bona fide therapies are similarly effective, both common factors and specific techniques likely contribute to therapeutic change.
Bion's pairing basic assumption involves two members forming a special relationship while the group invests messianic hope in their union - it functions as a group defence against anxiety, diverting from therapeutic work.
EMDR is NICE-recommended as first-line for PTSD alongside trauma-focused CBT - it involves processing traumatic memories with bilateral stimulation through an eight-phase protocol, with effect sizes comparable to TF-CBT.
The stages of change - precontemplation, contemplation, preparation, action, maintenance (with relapse) - guide therapeutic approach; motivational interviewing techniques should match the patient's current stage rather than assuming readiness for action.
Balanced alternative thoughts are evidence-based and realistic, not unrealistically positive - they aim to correct cognitive distortions by incorporating all available evidence, reducing the intensity of disproportionate emotional responses.
Transference is the unconscious replaying of past relational patterns with the therapist - it provides invaluable therapeutic material by making unconscious relational templates visible and available for interpretation and modification.
CBT for BDD includes mirror retraining (holistic rather than detail-focused viewing), cognitive restructuring of appearance beliefs, and ERP for checking and camouflaging - reassurance and cosmetic surgery are contraindicated as they maintain the disorder.
DEAR MAN (Describe, Express, Assert, Reinforce, Mindful, Appear confident, Negotiate) teaches effective assertiveness - it is complemented by GIVE skills for maintaining relationships and FAST skills for maintaining self-respect.
Early maladaptive schemas are self-defeating relational templates formed in childhood - Young identified 18 EMS in five domains, and schema therapy addresses them through limited reparenting, mode work, and experiential techniques alongside cognitive and behavioural strategies.
Open groups allow ongoing membership changes while closed groups maintain fixed membership throughout - the choice depends on clinical setting and therapeutic goals, with closed groups favouring deeper cohesion and open groups offering continuous availability.